# Single-deletion-mutant, third-generation rabies viral vectors allow nontoxic retrograde targeting of projection neurons with greatly increased efficiency

5 Lei Jin<sup>1</sup>, Heather A. Sullivan<sup>1</sup>, Mulangma Zhu<sup>1</sup>, Nicholas E. Lea<sup>1</sup>, Thomas K. Lavin<sup>1</sup>, Makoto 6 Matsuyama<sup>1</sup>, YuanYuan Hou<sup>1</sup>, and Ian R. Wickersham<sup>1\*</sup> 7

8 1. McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA
 \*Correspondence.

10

### 11 SUMMARY

12

13 Rabies viral vectors have become important components of the systems neuroscience toolkit, allowing both direct retrograde targeting of projection neurons and monosynaptic 14 tracing of inputs to defined postsynaptic populations, but the rapid cytotoxicity of first-15 generation ( $\Delta$ G) vectors limits their use to short-term experiments. We recently introduced 16 second-generation. double-deletion-mutant ( $\Delta$ GL) rabies viral vectors. showing that they 17 18 efficiently retrogradely infect projection neurons and express recombinases effectively but with little to no detectable toxicity; more recently, we have shown that  $\Delta$ GL viruses can be 19 20 used for monosynaptic tracing with far lower cytotoxicity than the first-generation system. 21 Here we introduce third-generation ( $\Delta L$ ) rabies viral vectors, which, like first-generation vectors, have only a single gene deleted from their genomes (in this case the viral 22 polymerase gene L) but which appear to be as nontoxic as second-generation ones: using 23 24 longitudinal structural and functional two-photon imaging in mouse visual cortex in vivo, we found that they did not kill labeled neurons or noticeably perturb their response properties 25 26 over the entire months-long courses of imaging. Although third-generation vectors are 27 therefore phenotypically very similar to second-generation ones, we show that they have the 28 major advantage of growing to much higher titers, and this key difference results in 25% -525% increased numbers of retrogradely labeled neurons in vivo. These  $\Delta L$  rabies viral 29 30 vectors therefore constitute a new state of the art for minimally perturbative, pathwayspecific expression of recombinases and transactivators in mammalian neurons selected on 31 the basis of their axonal projections. Because replication of deletion-mutant rabies viruses 32 within complementing cells is precisely the process that underlies monosynaptic tracing. 33 34 the higher replication efficiency of this new class of rabies viral vectors furthermore suggests the potential to provide the foundation of an improved nontoxic monosynaptic 35 36 tracing system. 37

### 38 INTRODUCTION

39 40 Since their introduction to neuroscience in 2007 (Wickersham et al., 2007a; Wickersham et al., 2007b), 41 recombinant rabies viral vectors have become widely-adopted tools in neuroscience, allowing "monosynaptic 42 tracing" of direct inputs to genetically-targeted starting postsynaptic neuronal populations (Jin et al., 2021b; 43 Wall et al., 2010; Wickersham et al., 2007b) as well as simple retrograde targeting of projection neurons when injected at the sites of these projection neurons' axonal arborizations (Chatterjee et al., 2018; 44 45 Wickersham et al., 2007a). These vectors are now used in a large number of laboratories worldwide and 46 have contributed to many high-impact studies of a wide variety of neural systems (Foster et al., 2021; 47 Miyamichi et al., 2011; Reardon et al., 2016; Schwarz et al., 2015; Siu et al., 2021; Smith et al., 2021; Stephenson-Jones et al., 2016; Wu et al., 2021; Yao et al., 2021). 48

Because first generation (" $\Delta$ G") rabies viral vectors (which have only the glycoprotein gene G deleted from their genomes) are cytotoxic (Chatterjee et al., 2018; Jin et al., 2021a; Jin et al., 2021b; Wickersham et al., 2007a), we recently introduced second-generation, " $\Delta$ GL" rabies viral vectors, which have both the glycoprotein gene G and the viral polymerase gene L (for "large" protein) deleted from their genomes (Chatterjee et al., 2018). Because the viral polymerase is absolutely required for transcription of all genes 54 from the rabies viral genome as well as for replication of the viral genome itself (Albertini et al., 2011; Finke 55 and Conzelmann, 2005; Horwitz et al., 2020; Morin et al., 2013; Ogino and Green, 2019; Te Velthuis et al., 56 2021), this additional deletion, by design, reduces gene expression to a minimal level (provided by the few 57 starting copies of the polymerase protein that are copackaged in each viral particle) that appears to be 58 completely harmless to the "infected" cells. Because transgene expression is reduced by the same degree, 59 we inserted the genes for Cre and Flpo recombinase, of which even low levels of expression are sufficient 60 to cause neuroscientifically-useful downstream effects such as expression of fluorophores or calcium 61 indicators in labeled cells (Chatterjee et al., 2018). We originally showed that these  $\Delta$ GL vectors are useful 62 tools for retrograde targeting of projection neurons (Chatterjee et al., 2018), and they have since been used 63 as such for applications including optogenetics and transcriptomic profiling (Ren et al., 2021; Roy et al., 2021; 64 Tasic et al., 2018). More recently, we have also shown that  $\Delta GL$  vectors can be complemented *in vivo* by 65 expression of both G and L in trans, yielding a second-generation monosynaptic tracing system with far lower 66 cytotoxicity than the first-generation version (Jin et al., 2021a).

67 Here we show that deletion of L alone appears to make rabies viral vectors as nontoxic as  $\Delta$ GL ones, 68 with labeled neurons surviving for at least months with apparently unperturbed visual response properties. 69 We find that these  $\Delta$ L vectors have a major growth advantage over  $\Delta$ GL ones in cell culture, attaining much 70 higher titers in complementing cells in culture. This higher replication efficiency translates into the practical 71 advantage of retrogradely labeling many more projection neurons when injected into these neurons' target 72 sites *in vivo*. 73

### 74 **RESULTS**

75

### 76 Construction and characterization of $\Delta L$ rabies virus

77 We began by constructing rabies viral vectors with only the polymerase gene deleted and characterized their 78 gene expression levels and growth dynamics in cell culture (Figure 1). Beginning with the genome plasmid 79 of a  $\Delta$ GL virus (Chatterjee et al., 2018), we reinserted the native glycoprotein gene in its original location, 80 followed by the gene for Cre recombinase (codon-optimized for mouse (Koresawa et al., 2000)) in an 81 additional transcriptional unit, then produced infectious virus by standard techniques (see Methods). We then 82 compared the gene expression levels of the resulting virus, RVAL-Cre, to those of first- and second-83 generation versions (RVAG-Cre and RVAGL-Cre, respectively) in cell culture (HEK 293T/17 cells) using 84 immunostaining for Cre as well as for the viral nucleoprotein, the highest-expressed rabies viral protein.

As shown in Figure 1A-D, whereas the first-generation ( $\Delta G$ ) virus expressed high levels of 85 86 nucleoprotein (which accumulated in cytoplasmic inclusions) and Cre (which localized to the nuclei), the  $\Delta GL$ 87 and  $\Delta L$  viruses had very low expression levels of both Cre and nucleoprotein, with the amount of label for 88 these proteins appearing much more similar to that seen in uninfected control cells than in cells infected with 89 the  $\Delta G$  virus. We also found similarly low transgene expression levels for  $\Delta L$  and  $\Delta GL$  viruses expressing 90 EGFP (Figure S1). However, just as we found previously for  $\Delta$ GL viruses (Chatterjee et al., 2018), the Cre 91 expressed by RVAL-Cre was sufficient to result in bright labeling of Cre reporter cells (bottom row in panels 92 A-D).

93 These results led us to predict that ∆L viruses would be as nontoxic as ∆GL ones, because of their 94 similarly low expression levels, and also that they would be similarly able to recombine reporter alleles *in* 95 *vivo* in order to allow downstream expression of useful transgene products such as fluorophores, activity 96 indicators, or opsins.

97 It remained to be seen, however, whether  $\Delta L$  viruses would have any particular advantage over  $\Delta GL$ 98 ones for purposes of retrogradely targeting neurons. Specifically, if they could not be produced at significantly 99 higher titers, they could be expected to label similar numbers of projection neurons, making  $\Delta L$  vectors a 100 mere curiosity of purely academic interest and with no relevance to neuroscientists. However, if they could 101 be grown to much higher titers than  $\Delta GL$  vectors, that could be expected to translate to the ability to 102 retrogradely label many more projection neurons, a desirable characteristic indeed for a tool for retrograde 103 targeting.

To examine this, we directly compared the ability of  $\Delta L$  virus to replicate in complementing cells with that of  $\Delta GL$  and  $\Delta G$  viruses (Figure 1E-F). We infected cell lines expressing L, G, or both with the three different generations of virus, at two different multiplicities of infection (MOI, measured in infectious units per cell): either very low (MOI = 0.01, "multi-step growth curves" (Gomme et al., 2010; Wang and Bushman, 2006)) or high (MOI = 1, "single-step growth curves". Following a one-hour incubation in the presence of the

viruses, we washed the cells twice with DPBS and applied fresh medium, then collected supernatant samples
 every 24 hours for five days after infection, then titered the samples on reporter cells.

111 As seen in Figure 1E-F, the results were clear: whereas the  $\Delta$ GL virus (on cells expressing both G 112 and L) never accumulated to titers higher than 2.37e6 iu/mL in either experiment, the  $\Delta L$  virus grew to 113 maximal titers of 6.51e6 iu/mL (at MOI of 0.01) and 1.96e7 iu/mL (at MOI of 1) on the same cell line 114 (expressing both G and L) and considerably higher (maximal titers of 1.31e7 iu/mL at MOI=0.01 and 2.60e7 115 iu/mL at MOI=1) on cells expressing L alone. The  $\Delta G$  virus grew to similarly high (or slightly higher, in the 116 MOI=1 case) titers to the ∆L one: 6.83e6 iu/mL at MOI=0.01 and 3.03e7 iu/mL at MOI=1, suggesting that 117 single-deletion-mutant rabies viruses may in general be easier to make at high titers than viruses with multiple 118 deleted genes. In non-complementing cells, by contrast, no such replication of any of these viruses ( $\Delta L$ ,  $\Delta GL$ , 119 or  $\Delta G$ ) occurred (Figure S2).

120 These findings that a  $\Delta L$  rabies virus could be grown to 11-fold higher titer than a matched  $\Delta GL$  one 121 led us to predict that  $\Delta L$  viruses would be superior tools for retrograde targeting *in vivo*, because their much 122 higher titers would result in retrograde infection of many more projection neurons.

#### 123

### 124 Retrograde targeting in vivo

To test this prediction, we made matched preparations of  $\Delta$ GL and  $\Delta$ L viruses expressing either Cre or Flpo (mouse-codon-optimized Flp recombinase (Raymond and Soriano, 2007)), then injected each of the four viruses in the somatosensory thalami of reporter mice (Ai14 (Madisen et al., 2010) for the Cre viruses, Ai65F (Daigle et al., 2018) for the Flpo ones; both lines express tdTomato following recombination by the respective recombinase). We sacrificed the mice at either 7 days or 4 weeks after injection, sectioned and imaged the brains by confocal microscopy, and counted the numbers of retrogradely labeled cells in cortex. Figure 2 shows the results.

132 As seen in panels 2B-E, for both recombinases, and at both timepoints, the  $\Delta L$  viruses significantly 133 outperformed the  $\Delta$ GL ones. For the Flpo viruses, the difference was dramatic: at the 1-week timepoint, the 134  $\Delta L$  virus labeled 24 times as many cells as the  $\Delta GL$  one (although this difference was not statistically 135 significant due to high variance in the  $\Delta L$  cohort: single factor ANOVA, p=0.275, n = 8 mice each group); by 136 the 4-week timepoint, the  $\Delta$ L-Flpo virus had labeled 6.25 times as many cells as the  $\Delta$ GL counterpart, a 137 difference that was extremely significant (single factor ANOVA, p=3.21E-04, n = 8 mice each group). For the 138 Cre viruses, the difference was smaller, presumably due a ceiling effect (see Discussion), but still highly 139 significant: at 1 week, the  $\Delta$ L-Cre virus had labeled 1.40 times as many cells as  $\Delta$ GL-Cre (single factor 140 ANOVA, p=4.20E-03; n = 4 mice each group); at the 4-week timepoint, the  $\Delta$ L-Cre virus had labeled 1.25 141 times as many cells as  $\Delta$ GL-Cre (single factor ANOVA, p=7.38E-04, n = 4 mice per group).

142 We also made some injections of RV<sub>Δ</sub>L-Cre, in thalami of Ai14 mice, with the much longer survival 143 times of 4 or 6 months (Fig 2F-G). The results at both of these longer survival times appeared very similar to 144 those at the shorter ones. Consistent with extensive prior literature on corticothalamic neurons (Alitto and 145 Usrey, 2003; Rockland, 2021; Rouiller and Welker, 2000) and with our previous results with corticothalamic 146 injections of AG and AGL viruses (Chatterjee et al., 2018; Wickersham et al., 2007a), the cells labeled in 147 cortex by both viruses at all timepoints were pyramidal neurons in layer 6, with a few in layer 5. Furthermore, 148 labeled neurons all appeared morphologically normal even months after injection, with the fine processes of axons and dendrites, including individual spines (rightmost images in 2F-G) clearly visible and without 149 150 blebbing or other obvious abnormalities.

As a further test of the flexibility of  $\Delta L$  vectors, we made a version expression the tetracycline transactivator (tTA) and injected it in the thalamus of Ai63 reporter mice (in which TRE-tight drives tdTomato expression) (Daigle et al., 2018). As seen in Figure S3, thousands of cortical thalamic cells were found retrogradely labeled at both 1-week and 4-week survival times, with no significant difference between the numbers at the two timepoints (single factor ANOVA, p = 0.772, n = 4 mice per group).

156

### 157 Longitudinal structural two-photon imaging in vivo

Because examining only postmortem tissue can be very misleading when attempting to determine whether a virus is nontoxic (see Jin et al. '21 (Jin et al., 2021a) for a detailed case study), we conducted longitudinal two-photon imaging of RV $\Delta$ L-labeled neurons *in vivo* (Figure 3). We injected either RV $\Delta$ GL-Cre (Chatterjee et al., 2018) or RV $\Delta$ L-Cre in primary visual cortex (V1) of Ai14 reporter mice, then imaged the resulting tdTomato-expressing neurons at or near the injection site beginning 7 days after injection and continuing every 7 or 14 days until 16 weeks postinjection. As seen in Figure 3, the results using the two viruses were very similar. For both  $\Delta$ GL and  $\Delta$ L viruses, the numbers of visibly labeled neurons increased significantly

165 between 1 week and 4 weeks postinjection (Figure 3D, G), by 56.27% for  $\Delta$ GL and by 67.77% for  $\Delta$ L (paired 166 t-tests, p = 1.319E-04 for  $\Delta$ GL, p = 1.003E-05 for  $\Delta$ L, n = 8 FOVs for each virus). Also for both viruses, the 167 numbers of visibly labeled neurons remained nearly completely constant from the 4-week timepoint onward 168 through all remaining imaging sessions (Figure 3E, H) (with the number of labeled cells at the 4-week 169 timepoint being not significantly different than that at the 12-week timepoint for the  $\Delta L$  virus (paired t-test, p 170 = 0.1327, n = 8 FOVs) and slightly (0.5%) lower for the  $\Delta$ GL virus (paired t-test, p = 0.0056, n = 8 FOVs). 171 See File S3 for all counts and statistical comparisons; see also Video S1 for a rendering of a group of  $\Delta L$ -172 labeled neurons at 2 weeks and again at 10 weeks.

173

### 174 Longitudinal functional two-photon imaging *in vivo*

175 We went on to examine the functional properties of RVAL-labeled neurons in vivo. As for the structural 176 imaging (see above), we injected RV<sub>Δ</sub>L-Cre in the primary visual cortices of reporter mice, in this case mice 177 that express the calcium indicator GCaMP6s (Chen et al., 2013) after Cre recombination (Figure 4). 178 Beginning one week later, we began imaged the calcium signals in the labeled neurons in a series of imaging 179 sessions that continued until 16 weeks postinjection, in the awake mice viewed visual stimuli consisting of 180 drifting gratings of different orientations and frequencies. Just as we found previously for  $\Delta GL$  viruses 181 (Chatteriee et al., 2018; Jin et al., 2021b), we found no signs of dysfunction in cells labeled by the third-182 generation vector for as long as we followed them (Figure 4; see also Figures S4 and S5. See File S4 for all 183 counts and statistical comparisons and Video S2 for an example of calcium responses in a group of cortical 184 neurons 16 weeks after injection of  $RV\Delta L$ -Cre).

### 186 **DISCUSSION**

187

185

Here we have shown that deletion of just the polymerase gene renders rabies viral vectors nontoxic, like second-generation ( $\Delta$ GL) vectors, but makes them much more efficient at replicating within complementing cells in culture. This ability to be grown to much higher titers results in significantly increased transduction of projection neurons within a given pathway. This more comprehensive access to projection neurons will increase the yield and efficacy of systems neuroscience experiments that depend on the retrograde targeting approach.

194 In the corticothalamic pathway that we have examined here, the advantage of a  $\Delta L$  vector over the 195  $\Delta$ GL equivalent was clearest in the case of the Flpo-expressing versions, with the  $\Delta$ L vector labeling 6.25 196 times as many neurons as the  $\Delta$ GL one did at four weeks postinjection. This ratio is of the same order of 197 magnitude as the ratio of the titers of the injected Flpo viruses (14.4: see Methods). By contrast, for the Cre-198 expressing versions, the advantage of the  $\Delta L$  vector over the  $\Delta GL$  one was more modest, labeling 1.25 times 199 as many cells, even though the ratio of the titers of these Cre vectors was even higher (20.5). Because the 200 absolute numbers of retrogradely labeled neurons, as well as the titers, were much higher for the Cre viruses 201 than for the corresponding Flpo ones, we presume that the smaller advantage of the  $\Delta L$  version seen in this 202 case was because of a ceiling effect, with the  $\Delta$ GL-Cre virus already labeling most of the available neurons 203 in this pathway.

204 One could certainly argue that the much higher titers that we are easily able to obtain with  $\Delta L$  vectors 205 could also, in theory, potentially be achieved with  $\Delta GL$  vectors, if enough effort were put into generating and 206 testing producer cell lines expressing both G and L in order to find one that expressed the two genes at just 207 the right ratio and levels. In practice, however, this hypothetical future research effort does not detract from 208 the fact that the best currently-existing preparations of  $\Delta L$  rabies viral vectors label many more cells than do 209  $\Delta GL$  ones, making them the better choice for retrograde targeting applications.

We note that, although here we have only demonstrated the use of  $\Delta L$  rabies viral vectors in mice, 210 211 they are also highly likely to work in a wide variety of mammalian species, because, apart from their shorter 212 RNA genomes, the structural properties of second- and third-generation rabies viral particles are identical to 213 those of first-generation ones, which have been successfully used in diverse mammalian species including rats (Cruz et al., 2021), cats (Connolly et al., 2012; Liu et al., 2013), ferrets (Hasse et al., 2019), and 214 215 macaques (Bragg et al., 2017; Briggs et al., 2016; Lyon et al., 2010; Nassi and Callaway, 2006, 2007; Nassi 216 et al., 2006; Siu et al., 2021; Yarch et al., 2017) (and even in fish (Dohaku et al., 2019; Satou et al., 2021; 217 Zhu et al., 2009) and frogs (Faulkner et al., 2021)).

218 Our findings here that  $\Delta L$  rabies viruses have extremely low expression levels and do not replicate 219 within (or spread beyond, *in vivo*) non-complementing cells are entirely consistent with similar findings in cell 220 culture in a recent report on an L-deficient rabies virus encoding firefly luciferase (Nakagawa et al., 2017).

221

A note about safety: our results strongly suggest that  $\Delta L$  rabies viruses are unable to replicate in the absence of complementation and moreover are harmless to any cells that they transduce. However, a mixture of  $\Delta L$  and  $\Delta G$  viruses could pose a safety risk, because such viruses will be mutually complementary. Care must therefore be taken to avoid contamination between  $\Delta L$  and  $\Delta G$  constructs – either packaged viruses or the genome plasmids used to make them – which would have the potential to create a selfcomplementing replication-competent mixture (see Hidaka et al. (Hidaka et al., 2018) for an example of such a self-complementing mixture).

229 Finally, we have recently shown (Jin et al., 2021b) that second-generation ( $\Delta$ GL) rabies viral vectors 230 can spread transsynaptically when complemented by provision of both G and L in trans. That is, 231 complementation of an L-deficient rabies virus (in that case, a G- and L-deficient virus that is also 232 complemented by G) allows it to spread beyond initially infected cells in vivo. It is therefore reasonable to 233 infer that provision of L in trans should allow third-generation,  $\Delta L$  rabies viral vectors to spread beyond initially 234 infected cells, given that we have shown here that such complementation in cell culture allows  $\Delta L$  viruses to 235 replicate very efficiently. We have also shown here, with the longitudinal two-photon imaging of labeled 236 neurons, that  $\Delta L$  viruses do not spread beyond initially infected cells in vivo in the absence of 237 complementation. Collectively, our results therefore suggest the outlines of a third-generation monosynaptic 238 tracing system based on  $\Delta L$  vectors complemented with L expression *in trans*. However, genetic targeting of 239 a  $\Delta L$  vector to specific starting cell types might appear elusive: in the first- and second-generation systems 240 (Jin et al., 2021b; Wickersham et al., 2007b), this targeting is achieved by packaging the rabies viral particles 241 with an avian retroviral envelope protein (EnvA) instead of its own envelope glycoprotein, so that they can 242 only infect cells that have been engineered to express EnvA's cognate receptor. On the face of it, this 243 pseudotyping strategy requires that G be deleted from the rabies viral genome, because expression of G by 244 the virus within the EnvA-expressing producer cells would result in the production of virions with membranes 245 populated by a mixture of EnvA and the rabies viral glycoprotein. If this challenge could be overcome, our present findings that  $\Delta L$  viruses replicate more readily in complementing cells, which is the fundamental 246 247 process central to monosynaptic tracing (Wickersham et al., 2007b), suggest that a third-generation 248 monosynaptic tracing system could be more efficient than the second-generation one. 249

### 250 **METHODS**

251

All experiments involving animals were conducted according to NIH guidelines and approved by the MIT
 Committee for Animal Care. Mice were housed 1-5 per cage under a normal light/dark cycle for all
 experiments.

### 255 256 **Cloning**

The third-generation rabies viral vector genome plasmids pRV $\Delta$ L-5Cre, pRV $\Delta$ L-5Flpo, and pRV $\Delta$ L-5tTA (Addgene 182964, 182965, and 182966) (the "5" denoting the position of the transgene relative to the other genes in the viral genome) was made by replacing the mCre gene in pRV $\Delta$ GL-4Cre (Chatterjee et al., 2018) (Addgene 98039) with the SAD B19 glycoprotein gene from pCAG-B19G (Chatterjee et al., 2018) (Addgene 59921) and either the mCre, Flpo (from pRV $\Delta$ G-4Flpo (Addgene 98040)), or tTA (from pAAVsyn-FLEX-splitTVA-EGFP-tTA (Liu et al., 2017) (Addgene 100798)) gene, separated by endogenous rabies viral transcriptional stop and start signals, using seamless cloning (InFusion (Takara) or HiFi (NEB)).

The piggyBac vector pB-TREtight-EGFP (Addgene 182967) was made by cloning the TRE-tight element from pAAV-TREtight-mTagBFP2-B19G (Liu et al., 2017) and the EGFP gene into pB-CAG-TEVp-IRES-mCherry (Addgene 174377) in place of the CAG-TEVp-IRES-mCherry sequences using HiFi seamless cloning (NEB).

The piggyBac plasmid pB-CAG-B19G-IRES-EGFP-WPRE-BGHpA (Addgene 178517) was made by cloning the CAG promoter from pCAG-B19G (Addgene 59921), the SAD B19 L gene, the EMCV IRES (Gallardo et al., 1997), the mCherry (Shaner et al., 2004) gene, and the woodchuck post-transcriptional regulatory element and bovine growth hormone polyadenylation signal from pCSC-SP-PW-GFP (Addgene 12337), into PB-CMV-MCS-EF1-Puro (System Biosciences #PB510B-1).

### 273274 Cell lines

The BHK-B19G3 cell line, expressing the SAD B19 strain rabies virus glycoprotein gene, was made by resorting BHK-B19G2 cells (Wickersham et al., 2010) on a BD Facs Aria cell sorter and retaining the

brightest 2% of EGFP-positive cells as well as the next-brightest 18%. Following the sort, both populations were expanded and refrozen, then thawed and tested for their efficacy at supporting replication of  $\Delta$ G virus; the second-brightest population ("BHK-B19G3\_2") was found to result in higher titers and is referred to here as BHK-B19G3.

The BHK-B19L cell line, expressing the SAD B19 strain rabies virus polymerase gene, was made by transfecting BHK-21 cells (ATCC CCL-10) with pCAG-hypBase (Jin et al., 2021a) and pB-CAG-B19L-IRES-mCherry-WPRE-BGHpA (Jin et al., 2021b) using Lipofectamine 2000 (Thermo Fisher 11668019), then expanding the cells and sorting on a FACS Aria sorter (BD) to collect the brightest 5%, as well as the next brightest 5%, of mCherry-expressing cells. The two collected populations were expanded and refrozen, then thawed and tested for their efficacy at supporting replication of  $\Delta$ L virus; the second-brightest population ("BHK-B19L\_2") was found to result in higher titers and is referred to here as BHK-B19L.

The BHK-B19L-G cell line, expressing the SAD B19 strain rabies virus polymerase and glycoprotein genes, was made by transfecting BHK-B19L cells (see above) with pCAG-hypBase and pB-CAG-B19G-IRES-EGFP-WPRE-BGHpA (see above), then expanding and sorting on a BD FACS Aria, keeping the brightest 5%, as well as the next brightest 5%, of EGFP-expressing cells which also expressed mCherry. The sorted cells were expanded and refrozen, then thawed and tested for their efficacy at supporting replication of  $\Delta$ GL virus; the brightest population ("BHK-B19L-G\_1") was found to result in higher titers and is referred to here as BHK-B19L-G.

295 The 293T-TREtight-EGFP cell line for titering tTA-expressing viruses was made by transfecting 296 HEK 293T/17 cells with pCAG-hypBase and pB-TREtight-EGFP (described above), then expanded and 297 sorted on a BD FACS Aria, excluding the brightest 2% of EGFP cells, and keeping four of the next brightest 298 EGFP cell populations. The sorted cells were expanded, frozen, and then thawed for testing their efficacy 299 at titering  $\Delta$ L-tTA virus. The fourth-brightest tranche of cells was used for subsequent titering of  $\Delta$ L-tTA 300 virus.

### 302 Rabies virus production and titering

303 The first-generation vector RV $\Delta$ G-4Cre, the second-generation vectors RV $\Delta$ GL-4Cre and RV $\Delta$ GL-4Flpo, 304 and the third-generation vectors RVAL-5Cre, RVAL-5Flpo, and RVAL-5tTA were rescued as described 305 previously (Chatteriee et al., 2018) using genome plasmids pRV $\Delta$ GL-4Cre, pRV $\Delta$ GL-4Flpo, pRV $\Delta$ L-5Cre, 306 pRV $\Delta$ L-5Flpo, and pRV $\Delta$ L-5tTA, respectively. For simplicity, these viruses are referred to in this manuscript 307 as RVAG-Cre, RVAGL-Cre, RVAGL-Flpo, RVAL-Cre, RVAL-Flpo, and RVAL-tTA, omitting the numbers 308 denoting the positions of the transgenes within the viral genomes. Rescue supernatants were collected and 309 filtered as described (Wickersham and Sullivan, 2015), titered on the reporter cell lines 293T-FLEX BC (for 310 Cre viruses) or 293T-F14F15S-BC (for Flpo viruses) (Jin et al., 2021a) as described (Wickersham et al., 311 2010), then used to infect BHK-B19G3, BHK-B19L-G, or BHK-B19L cells (see above) at multiplicities of 312 infection ranging from 0.1 to 1. Supernatants from these "P1" plates were collected and titered as 313 described (Wickersham and Sullivan, 2015); in some cases, these were used for a similar second passage 314 ("P2"). Purification and concentration of either P1 or P2 supernatants was as described (Wickersham et al., 315 2010), with supernatants treated with benzonase (Sigma 71206) (25 minute incubation at 37°C with 30 316 units/ml at) before ultracentrifugation. Concentrated viruses were aliguoted and frozen at -80°C. Rabies 317 viruses were titered on reporter cells (293T-FLEX-BC for Cre viruses, 293T-F14F15S-BC for Flpo viruses, 318 293T-TREtight-EGFP (see above) for RV∆L-tTA) as described (Wickersham et al., 2010), using a LUNA-II 319 cell counter (Logos Biosystems) instead of a hemocytometer for counting cells, and in some cases using 320 two-fold (as opposed to ten-fold) dilution series for more precise comparisons of titers.

321

301

### 322 Immunostaining, imaging, and flow cytometry of cultured cells

For anti-nucleoprotein and anti-Cre staining (for Figure 1): HEK 293T/17 (ATCC 11268) cells were plated on poly-L-lysine-coated coverslips in 24-well plates, then infected the following day with serial dilutions of RV $\Delta$ G-4Cre (Chatterjee et al., 2018), RV $\Delta$ GL-4Cre (Chatterjee et al., 2018), or RV $\Delta$ L-5Cre. Three days after infection, cells were fixed with 2% paraformaldehyde, washed repeatedly with

327 blocking/permeabilization buffer (0.1% Triton-X (Sigma) and 1% bovine serum albumin (Sigma) in PBS),

328 then labeled with a 1:100 dilution of anti-nucleoprotein monoclonal antibody blend (Light Diagnostics

- Rabies DFA Reagent, EMD Millipore 5100) as well as a 1:250 dilution of rabbit anti-Cre polyclonal antibody
- (Millipore Sigma 69050) followed by a 1:200 dilution of Alexa Fluor 594-conjugated donkey anti-rabbit
   secondary (Jackson Immuno 711-585-152).
- 332

For anti-EGFP staining (for Figure S1), HEK cells were plated as above, then infected the following day
with serial dilutions of RVΔG-4EGFP (Wickersham et al., 2010), RVΔGL-4EGFP (Chatterjee et al., 2018),
or RVΔL-5EGFP, with immunostaining three days postinfection, using a 1:1000 dilution of chicken anti-GFP
polyclonal antibody (Aves Labs, GFP-1020) and a 1:500 dilution of Alexa Fluor 594-conjugated donkey
anti-chicken secondary antibody (Jackson Immuno 703-585-155).

Immunostained cells on coverslips were mounted on slides using Prolong Diamond Antifade
 mounting medium (Thermo P36970) and imaged on a Zeiss LSM 900 confocal microscope using a 20x
 objective.

For matched flow cytometric analysis of immunostained cells, cells were plated in 24-well plates without poly-L-lysine-coated coverslips but otherwise immunostained as described above, then analyzed on an LSR II flow cytometer (BD) using FACS Diva software (BD). Histograms displayed in Figure 1 were smoothed using the FACS Diva "Smooth histogram" setting.

### 346 Viral growth analysis

347 For determining growth curves, BHK-B19G3, BHK-B19L-G, and BHK-B19L cells (see above) were plated 348 in 10 cm plates coated in poly-L-lysine in normal medium (10% fetal bovine serum (VWR 16777-014) and 349 antibiotic-antimycotic (Thermo 15240096) in DMEM (Thermo 11995073)) (Wickersham et al., 2010). The 350 following day, cells were infected with RVAG-4Cre(B19G), RVAGL-4Cre(B19G), or RVAL-5Cre(B19G) at 351 an MOI of either 1 (for single-step growth curves) or 0.01 (for multi-step growth curves), with viruses diluted 352 in normal medium at a total volume of 2 ml per plate, with each condition in triplicate. Following a one-hour 353 incubation, the virus-containing medium was aspirated, plates were washed twice in DPBS (Thermo 354 14190144), and 12 ml fresh medium was added to each plate before they were returned to the incubator. 355 Every 24 hours for the following five days, 200 µl of supernatant was collected from each plate; these 356 supernatant samples were filter-sterilized using a 96-well 0.45um PVDF filter plate (Millipore MSHVN4510), 357 then frozen at -80°C before all samples were thawed and titered on HEK 293T-FLEX-BC cells as described 358 above. 359

### 360 Mouse strains

361 The Cre-dependent tdTomato reporter line Ai14 (Madisen et al., 2010) was purchased from Jackson 362 Laboratory (catalog # 007914). The Flp-dependent tdTomato reporter line Ai65F was obtained by crossing the Cre- and Flp-dependent tdTomato double-reporter line Ai65D (Madisen et al., 2015) (Jackson 363 364 Laboratory 021875) to the Cre deleter line Meox2-Cre (Tallquist and Soriano, 2000) (Jackson Laboratory 365 003755), then breeding out the Meox2-Cre allele. An equivalent Ai65F line, made using a different Cre 366 deleter line, was described in Daigle et al. '18 (Daigle et al., 2018) and is now available from Jackson 367 Laboratory (catalog # 032864). The tTA-dependent tdTomato reporter line Ai63 (Daigle et al., 2018) was a 368 generous gift from Hongkui Zeng and Tanya Daigle. Mice used for the functional two-photon imaging 369 experiments were crosses of the Cre- and tTA-dependent GCaMP6s line Ai94D (Jackson Laboratory 370 024104) with the Cre-dependent tTA line ROSA:LNL:tTA (Wang et al., 2008) (Jackson Laboratory 011008). 371 All mice were maintained in a C57BL/6J (Jackson Laboratory 000664) background.

For experiments, adult mice of both sexes were used, of the following mouse strains. For retrograde
targeting using Cre-expressing viruses (Figure 2) and structural two-photon imaging (Figure 3): Ai14
heterozygotes. For retrograde targeting using Flpo-expressing viruses (Figure 2): Ai65F heterozygotes. For
retrograde targeting using RV∆L-tTA (Figure S3): Ai63 heterozygotes. For functional two-photon imaging
(Figures 4, S4, and S5): Ai94D x ROSA:LNL:tTA double homozygotes.

### 378 Stereotaxic injections

388

200 nl of rabies virus was injected into either somatosensory thalamus (VPM/Po, for figure 2) or primary 379 380 visual cortex (for two-photon experiments) of anesthetized adult mice using a stereotaxic instrument 381 (Stoelting Co., 51925) and a custom injection apparatus consisting of a hydraulic manipulator (Narishige, 382 MO-10) with headstage coupled via custom adaptors to a wire plunger advanced through pulled glass 383 capillaries (Drummond, Wiretrol II) back-filled with mineral oil and front-filled with viral vector solution (Lavin 384 et al., 2019). We have described this injection system in detail previously. Injection coordinates for VPM/Po 385 were: anteroposterior (AP) = -1.82 mm with respect to (w.r.t.) bregma, lateromedial (LM) = +1.54 mm w.r.t. 386 bregma, dorsoventral (DV) = -3.15 mm w.r.t the brain surface; injection coordinates for V1 cortex were: AP 387 = -2.70 mm w.r.t. bregma, LM = 2.50 mm w.r.t. bregma, DV = -0.26 mm w.r.t the brain surface.

For mice to be used for two-photon imaging, a 3 mm craniotomy was opened over primary visual cortex (V1). Glass windows composed of a 3mm-diameter glass coverslip (Warner Instruments CS-3R) glued (Optical Adhesive 61, Norland Products) to a 5mm-diameter glass coverslip (Warner Instruments CS-5R) were affixed over the craniotomy with Metabond (Parkell) after virus injection.

For the  $\Delta$ GL vs.  $\Delta$ L experiments (Figure 2), the four viruses were produced in parallel for direct comparison, and RV $\Delta$ L-Cre (6.16E+10 i.u./ml) or RV $\Delta$ GL-Cre (3.01E+09 i.u./ml) was injected into Ai14 (het) mice, and RV $\Delta$ L-Flpo (1.61E+09 i.u./ml) or RV $\Delta$ GL-4Flpo (1.12E+08 i.u./ml) was injected into Ai65F (het) mice. For the 4-month and 6-month experiments for Figure 2, RV $\Delta$ L-Cre (1.66E+10 i.u./ml) was injected into Ai14 (het) mice. For Figure S3, RV $\Delta$ L-tTA (3.63E+10 iu/ml) was injected into Ai63 (het) mice.

For two-photon structural experiments (Figure 3), RV∆GL-Cre (1.19E+10 iu/ml) or RV∆L-Cre
(1.66E+10 iu/ml diluted to 1.19E+10 iu/ml for matching to RV∆GL-Cre) was injected into Ai14 (het) mice.
For two-photon functional experiments in Figure 4, RV∆L-Cre (2.61E+10 iu/ml) was injected into
homo/homo Ai94D x ROSA:LNL:tTA mice.

402

### 403 **Perfusions, histology, and confocal imaging**

404 1 week to 6 months (see main text) after injection of rabies virus, anesthetized mice were transcardially 405 perfused with 4% paraformaldehyde. Brains were postfixed overnight in 4% paraformaldehyde in PBS on a 406 shaker at 4°C and cut into 50 µm coronal sections on a vibrating microtome (Leica, VT-1000S). Sections 407 were collected sequentially into 6 tubes containing cryoprotectant, so that each tube contained every sixth 408 section, then frozen at -20°C. Sections to be imaged were washed to remove cryoprotectant, then mounted 409 with Prolong Diamond Antifade mounting medium (Thermo Fisher P36970) and imaged on a confocal 410 microscope (Zeiss, LSM 900). To ensure that the confocal images included in the figures are 411 representative of each group, the images were taken after the counts were conducted, and the mouse with 412 the next higher number of labeled neurons than the average number for its group was selected for confocal 413 imaging. 414

### 415 Quantification of retrograde targeting

Coronal sections between 0.43mm anterior and 4.07mm posterior to bregma were imaged with an epifluorescence microscope for cell counting (Zeiss, Imager.Z2). Due to the high density of retrogradely labeled tdTomato neurons in the cortex at the injection site (VPM/Po), cells were counted using the Analyze Particle function in ImageJ (size in micron^2: 20-400; circularity: 0.20-1.00). Only one of the six series of sections (i.e., every sixth section: see above) was counted for each mouse. P-values for all comparisons were obtained using single-factor ANOVAs.

### 422

### 423 Structural two-photon imaging and image analysis

424 Beginning seven days after injection of each rabies virus and recurring at the subsequent indicated 425 timepoints (see main text) up to a maximum of 16 weeks following rabies virus injection, fields of view 426 (FOVs) were imaged on a Prairie/Bruker Ultima IV In Vivo two-photon microscope driven by a Spectra 427 Physics Mai-Tai Deep See laser with a mode locked Ti:sapphire laser emitting at a wavelength of 1020 nm 428 for excitation of tdTomato. In order to distinguish individual labeled neurons, FOVs were chosen some 429 distance away from the area of brightest tdTomato labeling. Two well-separated areas were chosen in 430 each mouse. For each imaging session, mice were reanesthetized and mounted via their headplates to a 431 custom frame, with ointment applied to protect their eyes and with a handwarmer maintaining body 432 temperature. Imaging parameters were as follows: image size 512 X 512 pixels (282.6 µm x 282.6 µm), 433 0.782 Hz frame rate, dwell time 4.0 µs, 2x optical zoom, Z-stack step size 1 µm. Image acquisition was 434 controlled with Prairie View 5.4 software. Laser power exiting the 20x water-immersion objective (Zeiss, W 435 plan-apochromat, NA 1.0) varied between 20 and 65 mW depending on focal plane depth (Pockels cell 436 value was automatically increased from 450 at the top section of each stack to 750 at the bottom section). 437 For the example images of labeled cells, maximum intensity projections (stacks of 100-200 µm) were made 438 with ImageJ software. Cell counting was automated using the "Analyze Particles" function in ImageJ. Plots 439 of cell counts were made with Prism 9 (GraphPad Software, San Diego, California).

440

### 441 Functional two-photon imaging and image analysis

For functional two-photon imaging of RV∆L-Cre-labeled cells, FOVs were slightly offset from the regions of

- brightest GCaMP6s label in left-hemisphere V1 in order to allow separate identification of individual cells.
- This imaging was performed using the same microscope (5.356-Hz frame rate, 1024X 128 pixels, 565.1

445 μm x 565.1 μm, dwell time 0.8 μs, 1x optical zoom, scan angle 45 degree) with the same objective and 446 laser (at 920 nm) as for the structural imaging experiments. Laser power at the objective ranged from 10 to 447 65 mW. Calcium imaging data were acquired in supragranular layers (100 to 200 µm deep). Surface 448 vasculature provided coarse fiducial markers for finding the same FOVs in different imaging sessions. 449 For these experiments, mice were awake and head-fixed. No behavioral training or reward was given. 450 Visual stimuli were generated in Matlab (R2015R version) with custom software based on Psychtoolbox 451 (http://psychtoolbox.org) and shown on the same LCD screen as in the widefield mapping experiments. 452 Each condition consisted of 2 s of a full-field sine wave grating drifting in one direction, presented at 80% 453 contrast with spatial frequency of 0.04 cycles/ degree, followed by 2 s of uniform mean luminance (gray). 454 All permutations of 12 directions (30° steps) and 5 temporal frequencies (1, 2, 4, 8 and 15 Hz) were shown, 455 in randomized order. The complete set was repeated 10 times, for a total stimulation period of 40 min per 456 FOV per session. Cells were then manually segmented, and single-cell fluorescence traces were extracted 457 by averaging the fluorescence of all pixels masking the soma, using ImageJ (version 2-0-0-rc-69) software. 458 The mean  $\Delta F/F$  over the full 2 s of each stimulus condition was used to calculate orientation tuning curves. 459 with background fluorescence (F) in  $\Delta$  F/F taken as the value of the trace immediately preceding a 460 condition, averaged over all conditions. The raw calcium traces from cells within individual FOVs (not 461 across FOVs, given different imaging conditions across animals and time points) were sorted by mean 462 fluorescence. Randomly colored ROI view images were created by suite2p (https://www.suite2p.org). For 463 'tuned' cells in Figure 4 panels F and G, the counts are based on all imaged neurons' individual tuning 464 curves, plotted in MATLAB; any cell showing response to a preferred orientation (including narrowly tuned 465 neurons and broadly tuned neurons) at any temporal frequency (1Hz, 2Hz, 4Hz, 8Hz, or 15Hz) was 466 counted manually as a tuned cell.

### 468 **RESOURCE AVAILABILITY** 469

470 All cell counts and statistical analyses are provided in Supplemental Information. The novel plasmids 471 described in this paper have been deposited with Addgene with the accession numbers given in Methods.

### 473 SUPPLEMENTAL INFORMATION

475 Supplemental information can be found online.

476 A preprint version of this paper is available on bioRxiv.

### 478 **ACKNOWLEDGMENTS**

479

467

472

474

477

We thank Tanya Daigle and Hongkui Zeng for sharing the Ai63 mouse line, Jacque Ip, Chloe Delepine, and Mriganka Sur for sharing mice, Chang Liu for assistance with optimizing MATLAB code for analysis of the functional imaging data, and Sara Beach for helpful suggestions on the manuscript. Research reported in this publication was supported by BRAIN Initiative awards RF1MH120017, U01MH106018, U01MH114829, and U19MH114830 from the National Institute of Mental Health.

### 485

### 486 **AUTHOR CONTRIBUTIONS** 487

L.J., N.E.L., M.M., Y.H., and M.Z. cloned constructs; H.A.S. produced viruses with assistance from L.J. and
M.Z.; H.A.S. conducted cell culture assays and immunocytochemistry; L.J., N.E.L., and T.K.L. performed
surgeries; L.J. and M.Z. performed histology and confocal imaging; L.J. performed two-photon imaging; L.J.,
M.Z., T.K.L., and N.E.L. managed mouse breeding; I.W. planned and supervised all work; I.W. and L.J. wrote
the manuscript with input from the other authors.

### 494 **DECLARATION OF INTERESTS**

495

496 I.R.W. is a consultant for Monosynaptix, LLC, advising on design of neuroscientific experiments.497

### 498 **REFERENCES**


- 500 Albertini, A.A., Ruigrok, R.W., and Blondel, D. (2011). Rabies virus transcription and replication. Advances 501 in virus research 79, 1-22.
- Alitto, H.J., and Usrey, W.M. (2003). Corticothalamic feedback and sensory processing. Curr Opin Neurobiol 13, 440-445.
- 504 Bragg, E.M., Fairless, E.A., Liu, S., and Briggs, F. (2017). Morphology of visual sector thalamic reticular 505 neurons in the macaque monkey suggests retinotopically specialized, parallel stream-mixed input to the 506 lateral geniculate nucleus. J Comp Neurol 525, 1273-1290.
- 507 Briggs, F., Kiley, C.W., Callaway, E.M., and Usrey, W.M. (2016). Morphological Substrates for Parallel 508 Streams of Corticogeniculate Feedback Originating in Both V1 and V2 of the Macaque Monkey. Neuron *90*,
- 509 388-399.
- 510 Chatterjee, S., Sullivan, H.A., MacLennan, B.J., Xu, R., Hou, Y., Lavin, T.K., Lea, N.E., Michalski, J.E.,
- 511 Babcock, K.R., Dietrich, S., *et al.* (2018). Nontoxic, double-deletion-mutant rabies viral vectors for retrograde 512 targeting of projection neurons. Nat Neurosci *21*, 638-646.
- 513 Chen, T.W., Wardill, T.J., Sun, Y., Pulver, S.R., Renninger, S.L., Baohan, A., Schreiter, E.R., Kerr, R.A.,
- 514 Orger, M.B., Jayaraman, V., *et al.* (2013). Ultrasensitive fluorescent proteins for imaging neuronal activity. 515 Nature *499*, 295-300.
- 516 Connolly, J.D., Hashemi-Nezhad, M., and Lyon, D.C. (2012). Parallel feedback pathways in visual cortex of 517 cats revealed through a modified rabies virus. J Comp Neurol *520*, 988-1004.
- 518 Cruz, A.M., Kim, T.H., and Smith, R.J. (2021). Monosynaptic Retrograde Tracing From Prelimbic Neuron 519 Subpopulations Projecting to Either Nucleus Accumbens Core or Rostromedial Tegmental Nucleus. Front
- 520 Neural Circuits *15*, 639733.
- Daigle, T.L., Madisen, L., Hage, T.A., Valley, M.T., Knoblich, U., Larsen, R.S., Takeno, M.M., Huang, L., Gu,
  H., Larsen, R., *et al.* (2018). A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-
- 523 Cell-Type Targeting and Functionality. Cell *174*, 465-480 e422.
- 524 Dohaku, R., Yamaguchi, M., Yamamoto, N., Shimizu, T., Osakada, F., and Hibi, M. (2019). Tracing of 525 Afferent Connections in the Zebrafish Cerebellum Using Recombinant Rabies Virus. Front Neural Circuits 526 *13*, 30.
- 527 Faulkner, R.L., Wall, N.R., Callaway, E.M., and Cline, H.T. (2021). Application of Recombinant Rabies Virus 528 to Xenopus Tadpole Brain. eNeuro.
- 529 Finke, S., and Conzelmann, K.K. (2005). Replication strategies of rabies virus. Virus Res.
- 530 Foster, N.N., Barry, J., Korobkova, L., Garcia, L., Gao, L., Becerra, M., Sherafat, Y., Peng, B., Li, X., Choi, 531 J.H., *et al.* (2021). The mouse cortico-basal ganglia-thalamic network. Nature *598*, 188-194.
- 532 Gallardo, H.F., Tan, C., and Sadelain, M. (1997). The internal ribosomal entry site of the 533 encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T 534 lymphocytes. Gene Ther *4*, 1115-1119.
- 535 Gomme, E.A., Faul, E.J., Flomenberg, P., McGettigan, J.P., and Schnell, M.J. (2010). Characterization of a 536 single-cycle rabies virus-based vaccine vector. Journal of virology *84*, 2820-2831.
- 537 Hasse, J.M., Bragg, E.M., Murphy, A.J., and Briggs, F. (2019). Morphological heterogeneity among 538 corticogeniculate neurons in ferrets: quantification and comparison with a previous report in macaque 539 monkeys. J Comp Neurol *527*, 546-557.
- Hidaka, Y., Lim, C.K., Takayama-Ito, M., Park, C.H., Kimitsuki, K., Shiwa, N., Inoue, K.I., and Itou, T. (2018).
  Segmentation of the rabies virus genome. Virus Res 252, 68-75.
- Horwitz, J.A., Jenni, S., Harrison, S.C., and Whelan, S.P.J. (2020). Structure of a rabies virus polymerase complex from electron cryo-microscopy. Proc Natl Acad Sci U S A *117*, 2099-2107.
- Jin, L., Matsuyama, M., Sullivan, H.A., Zhu, M., Lavin, T.K., Hou, Y., Lea, N.E., Pruner, M.T., Ferdínez,
  M.L.D., and Wickersham, I.R. (2021a). Rabies virus with a destabilization domain added to its nucleoprotein
  spreads between neurons only if the domain is removed. bioRxiv, 550640.
- Jin, L., Sullivan, H.A., Zhu, M., Lavin, T.K., Matsuyama, M., Lea, N.E., Xu, R., Hou, Y., Rutigliani, L., Pruner,
  M., *et al.* (2021b). Long-term labeling and imaging of synaptically-connected neuronal networks <em>in
  vivo</em> using nontoxic, double-deletion-mutant rabies viruses. bioRxiv, 2021.2012.2004.471186.
- 550 Koresawa, Y., Miyagawa, S., Ikawa, M., Matsunami, K., Yamada, M., Shirakura, R., and Okabe, M. (2000).
- 551 Synthesis of a new Cre recombinase gene based on optimal codon usage for mammalian systems. J 552 Biochem 127, 367-372.
- Lavin, T.K., Jin, L., and Wickersham, I.R. (2019). Monosynaptic tracing: a step-by-step protocol. J Chem Neuroanat, 101661.

- Liu, K., Kim, J., Kim, D.W., Zhang, Y.S., Bao, H., Denaxa, M., Lim, S.A., Kim, E., Liu, C., Wickersham, I.R., *et al.* (2017). Lhx6-positive GABA-releasing neurons of the zona incerta promote sleep. Nature *548*, 582-587.
- Liu, Y.J., Ehrengruber, M.U., Negwer, M., Shao, H.J., Cetin, A.H., and Lyon, D.C. (2013). Tracing inputs to inhibitory or excitatory neurons of mouse and cat visual cortex with a targeted rabies virus. Curr Biol *23*, 1746-1755.
- 561 Lyon, D.C., Nassi, J.J., and Callaway, E.M. (2010). A disynaptic relay from superior colliculus to dorsal stream visual cortex in macague monkey. Neuron *65*, 270-279.
- 563 Madisen, L., Garner, A.R., Shimaoka, D., Chuong, A.S., Klapoetke, N.C., Li, L., van der Bourg, A., Niino, Y.,
- Egolf, L., Monetti, C., *et al.* (2015). Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. Neuron *85*, 942-958.
- 566 Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala, H.A., Gu, H., Ng, L.L., Palmiter, R.D., 567 Hawrylycz, M.J., Jones, A.R., *et al.* (2010). A robust and high-throughput Cre reporting and characterization 568 system for the whole mouse brain. Nature neuroscience *13*, 133-140.
- 569 Miyamichi, K., Amat, F., Moussavi, F., Wang, C., Wickersham, I., Wall, N.R., Taniguchi, H., Tasic, B., Huang, 570 Z.J., He, Z., *et al.* (2011). Cortical representations of olfactory input by trans-synaptic tracing. Nature *472*, 571 191-196.
- 572 Morin, B., Kranzusch, P.J., Rahmeh, A.A., and Whelan, S.P. (2013). The polymerase of negative-stranded 573 RNA viruses. Current opinion in virology *3*, 103-110.
- 574 Nakagawa, K., Kobayashi, Y., Ito, N., Suzuki, Y., Okada, K., Makino, M., Goto, H., Takahashi, T., and
- 575 Sugiyama, M. (2017). Molecular Function Analysis of Rabies Virus RNA Polymerase L Protein by Using an 576 L Gene-Deficient Virus. J Virol *91*.
- 577 Nassi, J.J., and Callaway, E.M. (2006). Multiple circuits relaying primate parallel visual pathways to the 578 middle temporal area. J Neurosci *26*, 12789-12798.
- Nassi, J.J., and Callaway, E.M. (2007). Specialized circuits from primary visual cortex to V2 and area MT.
   Neuron *55*, 799-808.
- Nassi, J.J., Lyon, D.C., and Callaway, E.M. (2006). The parvocellular LGN provides a robust disynaptic input
   to the visual motion area MT. Neuron *50*, 319-327.
- 583 Ogino, T., and Green, T.J. (2019). Transcriptional Control and mRNA Capping by the GDP 584 Polyribonucleotidyltransferase Domain of the Rabies Virus Large Protein. Viruses *11*.
- 585 Raymond, C.S., and Soriano, P. (2007). High-efficiency FLP and PhiC31 site-specific recombination in 586 mammalian cells. PLoS One 2, e162.
- 587 Reardon, T.R., Murray, A.J., Turi, G.F., Wirblich, C., Croce, K.R., Schnell, M.J., Jessell, T.M., and Losonczy,
- 588 A. (2016). Rabies Virus CVS-N2c(DeltaG) Strain Enhances Retrograde Synaptic Transfer and Neuronal 589 Viability. Neuron *89*, 711-724.
- Ren, W., Centeno, M.V., Wei, X., Wickersham, I., Martina, M., Apkarian, A.V., and Surmeier, D.J. (2021).
  Adaptive alterations in the mesoaccumbal network after peripheral nerve injury. Pain *162*, 895-906.
- 592 Rockland, K.S. (2021). A Closer Look at Corticothalamic "Loops". Front Neural Circuits 15, 632668.
- 593 Rouiller, E.M., and Welker, E. (2000). A comparative analysis of the morphology of corticothalamic 594 projections in mammals. Brain Res Bull *53*, 727-741.
- Roy, D.S., Zhang, Y., Aida, T., Choi, S., Chen, Q., Hou, Y., Lea, N.E., Skaggs, K.M., Quay, J.C., Liew, M.,
- *et al.* (2021). Anterior thalamic dysfunction underlies cognitive deficits in a subset of neuropsychiatric disease models. Neuron *109*, 2590-2603 e2513.
- Satou, C., Neve, R.L., Oyibo, H.K., Zmarz, P., Huang, K.-H., Bouldoires, E.A., Mori, T., Higashijima, S.-i.,
  Keller, G.B., and Friedrich, R.W. (2021). A viral toolbox for conditional and transneuronal gene expression in
  zebrafish. bioRxiv. 2021.2003.2025.436574.
- 601 Schwarz, L.A., Miyamichi, K., Gao, X.J., Beier, K.T., Weissbourd, B., DeLoach, K.E., Ren, J., Ibanes, S.,
- Malenka, R.C., Kremer, E.J., *et al.* (2015). Viral-genetic tracing of the input-output organization of a central noradrenaline circuit. Nature.
- 604 Shaner, N.C., Campbell, R.E., Steinbach, P.A., Giepmans, B.N., Palmer, A.E., and Tsien, R.Y. (2004).
- 605 Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent 606 protein. Nat Biotechnol 22, 1567-1572.
- 607 Siu, C., Balsor, J., Merlin, S., Federer, F., and Angelucci, A. (2021). A direct interareal feedback-to-608 feedforward circuit in primate visual cortex. Nat Commun *12*, 4911.
- 609 Smith, M.L., Asada, N., and Malenka, R.C. (2021). Anterior cingulate inputs to nucleus accumbens control 610 the social transfer of pain and analgesia. Science *371*, 153-159.

- 611 Stephenson-Jones, M., Yu, K., Ahrens, S., Tucciarone, J.M., van Huijstee, A.N., Mejia, L.A., Penzo, M.A.,
- Tai, L.H., Wilbrecht, L., and Li, B. (2016). A basal ganglia circuit for evaluating action outcomes. Nature *539*, 289-293.
- Tallquist, M.D., and Soriano, P. (2000). Epiblast-restricted Cre expression in MORE mice: a tool to distinguish
   embryonic vs. extra-embryonic gene function. Genesis 26, 113-115.
- Tasic, B., Yao, Z., Graybuck, L.T., Smith, K.A., Nguyen, T.N., Bertagnolli, D., Goldy, J., Garren, E., Economo,
- M.N., Viswanathan, S., *et al.* (2018). Shared and distinct transcriptomic cell types across neocortical areas.
  Nature *563*, 72-78.
- Te Velthuis, A.J.W., Grimes, J.M., and Fodor, E. (2021). Structural insights into RNA polymerases of negative-sense RNA viruses. Nat Rev Microbiol *19*, 303-318.
- Wall, N.R., Wickersham, I.R., Cetin, A., De La Parra, M., and Callaway, E.M. (2010). Monosynaptic circuit
   tracing in vivo through Cre-dependent targeting and complementation of modified rabies virus. P Natl Acad
   Sci USA.
- Wang, G.P., and Bushman, F.D. (2006). A statistical method for comparing viral growth curves. J Virol Methods *135*, 118-123.
- Wang, L., Sharma, K., Deng, H.X., Siddique, T., Grisotti, G., Liu, E., and Roos, R.P. (2008). Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology.
- 628 Neurobiol Dis 29, 400-408.
- Wickersham, I.R., Finke, S., Conzelmann, K.K., and Callaway, E.M. (2007a). Retrograde neuronal tracing with a deletion-mutant rabies virus. Nature Methods *4*, 47-49.
- 631 Wickersham, I.R., Lyon, D.C., Barnard, R.J., Mori, T., Finke, S., Conzelmann, K.K., Young, J.A., and
- 632 Callaway, E.M. (2007b). Monosynaptic restriction of transsynaptic tracing from single, genetically targeted 633 neurons. Neuron *53*, 639-647.
- 634 Wickersham, I.R., and Sullivan, H.A. (2015). Rabies viral vectors for monosynaptic tracing and targeted 635 transgene expression in neurons. Cold Spring Harb Protoc *2015*, 375-385.
- Wickersham, I.R., Sullivan, H.A., and Seung, H.S. (2010). Production of glycoprotein-deleted rabies viruses
   for monosynaptic tracing and high-level gene expression in neurons. Nature protocols *5*, 595-606.
- 638 Wu, X., Morishita, W., Beier, K.T., Heifets, B.D., and Malenka, R.C. (2021). 5-HT modulation of a medial 639 septal circuit tunes social memory stability. Nature *599*, 96-101.
- Yao, S., Wang, Q., Hirokawa, K.E., Ouellette, B., Ahmed, R., Bomben, J., Brouner, K., Casal, L., Caldejon,
- 641 S., Cho, A., *et al.* (2021). A whole-brain monosynaptic input connectome to neuron classes in mouse visual 642 cortex. bioRxiv, 2021.2009.2029.459010.
- Yarch, J., Federer, F., and Angelucci, A. (2017). Local Circuits of V1 Layer 4B Neurons Projecting to V2
   Thick Stripes Define Distinct Cell Classes and Avoid Cytochrome Oxidase Blobs. J Neurosci 37, 422-436.
- Zhu, P., Narita, Y., Bundschuh, S.T., Fajardo, O., Scharer, Y.P., Chattopadhyaya, B., Bouldoires, E.A.,
- 646 Stepien, A.E., Deisseroth, K., Arber, S., *et al.* (2009). Optogenetic Dissection of Neuronal Circuits in Zebrafish
- 647 using Viral Gene Transfer and the Tet System. Front Neural Circuits 3, 21.
- 648 649

### 650 FIGURES






### 652 653

#### Figure 1. Rabies virus with just the polymerase gene deleted ( $\Delta L$ ) is phenotypically similar to double-deletion-mutant ( $\Delta GL$ ) virus but replicates to much higher titers within complementing cells. (A-D) Deletion of just the polymerase gene L reduces transgene expression to levels that are very low but

- 657 still sufficient to support reporter allele recombination in Cre reporter cells.
- 658 (A) Negative controls (uninfected cells). Top: Uninfected HEK 293T cells stained for rabies virus
- nucleoprotein (green) and for Cre (red). Histograms to right of panels show flow cytometric quantification of
   baseline fluorescence of uninfected cells in these channels. Bottom: Uninfected reporter cells which
   express mCherry following Cre recombination. Little signal is seen in these negative controls.
- 662 (B) Cells infected with a first-generation ( $\Delta$ G) vector expressing Cre. Both Cre and N are expressed at very 663 high levels, and infected Cre reporter cells brightly express mCherry (note that dilutions at which roughly 664 half of cells were infected were chosen for this figure).
- 665 (C) Consistent with our previous findings (Chatterjee et al., 2018), expression of both nucleoprotein and
- 666 Cre from a second-generation ( $\Delta$ GL) vector is drastically reduced with respect to the first-generation vector, 667 with expression levels comparable to those seen in negative controls. Despite this, the low Cre levels are 668 still high enough to activate mCherry expression in reporter cells.
- 669 (D) A third-generation (ΔL) vector expresses nucleoprotein and Cre at similarly very low levels, but again
- 670 Cre expression is nonetheless high enough to successfully activate mCherry expression in reporter cells.
- 671 (E-F) Third-generation ( $\Delta$ L) vectors grow to much high titers in cultured cells than second-generation ( $\Delta$ GL) 672 ones do.
- 673 (E) Viral titers in supernatants of complementing cells (expressing L, G, or both) infected with  $\Delta$ L,  $\Delta$ GL, or
- $\Delta G$  viruses at a multiplicity of infection (MOI) of 0.01 ("multi-step growth curves"), with supernatants
- 675 collected every 24 hours for five days. Whereas a  $\Delta$ GL virus only achieves 1.05E+06 infectious units
- 676 (i.u.)/ml over the duration of the experiment, the  $\Delta L$  virus grows to 6.2-fold higher on the same cell line, and
- 12.5-fold higher on a line expressing L alone. The highest ΔL titers obtained in this experiment were
- significantly higher than the highest obtained with a first-generation ( $\Delta G$ ) virus (single-factor ANOVA, p = 3.24E-03, n = 3 replicates per condition).
- 680 (F) Similarly, at a MOI of 1 ("single-step" growth curves), the  $\Delta$ GL virus titer peaks at 2.37E+06 i.u./ml,
- 681 whereas the peak titer of the  $\Delta$ L virus is 2.60E+07 i.u./ml, 11.0-fold higher than that of the  $\Delta$ GL virus and
- not significantly different from that of the  $\Delta G$  virus (single-factor ANOVA, p = 0.105, n = 3 replicates per
- 683 condition). Graphs in (E-F) show means ± s.e.m.



#### 684 685

## 686Figure 2. Third-generation ( $\Delta$ L) rabies viral vectors retrogradely label many more projection687neurons in vivo than do second-generation ( $\Delta$ GL) ones and leave cells morphologically normal for688at least six months.


689 (A) Design of experiments retrogradely targeting corticothalamic cells in reporter mice. Either second-690 generation vector RV $\Delta$ GL-Flpo or RV $\Delta$ GL-Cre, or third-generation vector RV $\Delta$ L-Flpo or RV $\Delta$ L-Cre, was 691 injected into somatosensory thalamus (VPM/Po) of either Ai65F (Flpo reporter) or Ai14 (Cre reporter). Mice 692 were perfused 1 week (b, d), 4 weeks (c, e), 4 months (f), or 6 months later (g).

693 (B-E) Efficacy comparison of Flpo- and Cre-expressing  $\Delta$ GL and  $\Delta$ L vectors.

- (B) Corticothalamic neurons in S1 of Ai65F mice labeled with RV $\Delta$ GL-Flpo (left) or RV $\Delta$ L-Flpo (center) at 1 week postinjection. Scale bar: 200 µm, applies to both images. Counts of labeled cortical neurons are shown at right (each data point is the total number in one series consisting of every sixth 50 µm section from a given brain - see Methods). The  $\Delta$ L virus labeled 24 times as many cortical neurons than the  $\Delta$ GL virus did, although the difference in this case is not significant due to high variance (single-factor ANOVA, p = 0.0608, n = 8 mice per group).
- 700 (C) Corticothalamic neurons in S1 of Ai65F mice labeled with RV∆GL-Flpo (left) or RV∆L-Flpo (center) at 4
- 701 weeks postinjection. Scale bar: 200 µm, applies to both images. Counts of labeled cortical neurons are
- shown at right. The  $\Delta L$  virus labeled 6.25 times as many cortical neurons than the  $\Delta GL$  virus did, an
- extremely significant difference (single-factor ANOVA, p = 0.000321, n = 8 mice per group).
- 704 (D) Corticothalamic neurons in S1 of Ai14 mice labeled with RV∆GL-Cre (left) or RV∆L-Cre (center) at 1
- 705 week postinjection. Scale bar: 200 μm, applies to both images. Counts of labeled cortical neurons are

- shown at right. The  $\Delta L$  virus labeled 1.4 times as many cortical neurons than the  $\Delta GL$  virus did, a highly significant difference (single-factor ANOVA, p = 0.00420, n = 8 mice per group).
- (E) Corticothalamic neurons in S1 of Ai14 mice labeled with RV $\Delta$ GL-Cre (left) or RV $\Delta$ L-Cre (center) at 4
- 709 weeks postinjection. Scale bar: 200 µm, applies to both images. Counts of labeled cortical neurons are
- shown at right. The  $\Delta$ L virus labeled 1.25 times as many cortical neurons than the  $\Delta$ GL virus did, an
- 711 extremely significant difference (single-factor ANOVA,  $\vec{p} = 0.000738$ , n = 8 mice each group).
- (F) Corticothalamic neurons in S1 of Ai14 mice labeled with RVAL-Cre at 4 months postinjection. Cells
- appear morphologically completely normal, with no blebbing or decomposition of processes. Scale bars:
- 714 200  $\mu$ m (left image) and 2  $\mu$ m (right image).
- (G) Corticothalamic neurons in S1 of Ai14 mice labeled with RVAL-Cre at 6 months postinjection. Cells still
- appear morphologically completely normal. Scale bars: 200 µm (left image) and 2 µm (right image).

bioRxiv preprint doi: https://doi.org/10.1101/2022.02.23.481706; this version posted April 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.



717 718

### Figure 3. Neurons labeled by $\Delta L$ rabies virus survive for at least 16 weeks.

(A) Experimental design for longitudinal structural two-photon imaging *in vivo*. Second-generation ( $\Delta$ GL) or third-generation ( $\Delta$ L) virus expressing Cre was injected in primary visual cortex of reporter mice, then the injection sites were imaged repeatedly for the following 16 weeks.

(B) Example renderings of the same volume of cortex labeled by RV∆L-Cre and imaged with a two-photon
 microscope at two different timepoints, 2 weeks (left) and 10 weeks (right). Every labeled neuron visible at
 2 weeks is still present at 10 weeks. Scale bar: 50 µm. See also Video S1.


726 (C) & (F), Example two-photon images of single fields of view (FOV) of cortex labeled by either the second-727 generation vector  $RV\Delta GL$ -Cre (C) or the third-generation vector  $RV\Delta L$ -Cre (F), imaged at different

timepoints, from 1 week (top left) to 12 weeks (bottom right). All labeled neurons visible at earlier

timepoints are still present at later ones, for both viruses. Scale bars: 50 µm, apply to all images.

- 730 (D) & (G), Absolute numbers of cells visibly labeled by  $RV\Delta GL$ -Cre (D) or  $RV\Delta L$ -Cre (G) for all structural
- FOVs in the study, at the 1-week and 4-week timepoints. Numbers of visibly labeled cells increased by
- 732 56.27% for  $\Delta$ GL and by 67.77% for  $\Delta$ L, as we found previously for second-generation vectors (Chatterjee
- et al., 2018)), suggesting accumulation and persistent activity of recombinase on this timescale. These
- increases were both extremely significant (one-tailed paired t-tests, p = 0.000132 ( $\Delta$ GL) and 0.00001003 ( $\Delta$ L), n = 8 FOVs each virus), but there was no significant difference between the increases seen for the
- 736 two viruses (two-tailed unpaired t-test, p = 0.5187, n = 8 FOVs per group).
- 737 (E) & (H), Percentages of cells visibly labeled by  $RV\Delta GL$ -Cre (E) and  $RV\Delta L$ -Cre (H) over time, relative to 738 the numbers visible at 1 week after rabies injection; each connected set of dots represents numbers seen
- in a given FOV at the different time points. For both viruses, the numbers of labeled neurons remain nearly

constant from the 4-week timepoint onward, as we found previously (Chatterjee et al., 2018) for  $\Delta$ GL virus. Imaging was discontinued for some mice at weeks 12 or 14 due to cloudiness of the optical windows.




#### 742 743

### Figure 4. △L rabies virus does not appear to perturb neurons' visual response properties for at least 16 weeks.

746 (A) Experimental design for longitudinal functional two-photon imaging *in vivo*.  $\Delta L$  virus expressing Cre was

- 747 injected in primary visual cortex of reporter mice expressing GCaMP6s (Chen et al., 2013) after Cre
- recombination, then the injection sites were imaged while the awake mice were presented with drifting
- grating stimuli of different orientations and temporal frequencies, repeatedly for 16 weeks following virusinjection.
- (B) Example FOV from a GCaMP6s imaging session 16 weeks after RV injection. Individual analyzed cells
   are randomly pseudocolored. This is the same FOV as shown in Video S2. Scale bar: 50 µm.
- 753 (C-D) Long-term stability of orientation and temporal frequency tuning in RV<sub>Δ</sub>L-Cre-labeled neurons. The
- top rows show maximum intensity projections of the imaged GCaMP6s signal in two different FOVs at
- three different timepoints for each FOV. Scale bars: 20 µm, apply to all images. Visual response tuning
- curves of the two circled cells in each FOV at the corresponding timepoint, obtained with drifting gratings
- 757 presented at 12 directions of motion and 5 temporal frequencies (TF) (mean  $\Delta$ F/F ± s.e.m., averaged over
- 10 repeats), are shown under each image. More examples from the same FOV are shown in Figure S5.

- 759 (E) Single-cell fluorescence time courses for 120 cells at the 12-week timepoint, showing activity over all
- five temporal frequencies (mean  $\Delta F/F$ , averaged over 10 repeats). Cells are ranked in descending order of 760 761 total activity. Scale bar: 10 s.
- (F) Percentages of labeled cells that were visually tuned (see Methods), from 6 different FOVs in 3 mice 762
- 763 imaged over 14 weeks. Connected sets of dots in a given color indicate data from a single mouse (data 764 from 2 FOVs are shown per mouse).
- 765 (G) Comparison of the percentages of labeled cells that were visually tuned at 2 weeks and 14 weeks. The
- 766 percentages increased moderately but significantly between the two timepoints, from 60% to 68% (paired
- 767 two-sample t-test, p = 0.0178, n = 6).
- 768
- 769





### **Figure S1.** $\Delta$ L and $\Delta$ GL viruses express EGFP at similarly low levels, Related to Figure 1


Confocal images and flow cytometric histograms showing native and immunostained EGFP signal in uninfected cells (A) and cells infected with first-generation ( $\Delta$ G) virus (B), second-generation ( $\Delta$ GL) virus (C), or third-generation virus (D) expressing EGFP. Scale bar: 50 µm, applies to all images.

- 778
- 779

в

<sup>A</sup> Multi-step growth curves (MOI=0.01)

Single-step growth curves (MOI=1)



780 781

### Figure S2. $\Delta$ G, $\Delta$ GL, and $\Delta$ L viruses do not propagate in non-complementing cells, Related to Figure

783 **1** 

Viral titers in supernatants of BHK-21 cells not expressing any rabies viral genes, infected with  $\Delta L$ ,  $\Delta GL$ , or  $\Delta G$  viruses at a multiplicity of infection (MOI) of 0.01 ("multi-step growth curves", panel A) or 1 ("singlestep" growth curves, panel B), with supernatants collected every 24 hours for five days. Graphs show mean  $\pm$  s.e.m. Black lines show negative control "titers" calculated from uninfected reporter cells (mean  $\pm$  s.e.m.

788 of 10 samples). Note that the titers in these graphs are 3-4 orders of magnitude lower than those obtained

on complementing cells (Figure 1).

### 791 File S1. Titers and statistics for growth dynamics experiments, Related to Figure 1

792

793 See following pages.

ACS data from Single-step growth curves (Infectious units/mL)	24hr	48hr	72hr	96hr	120hr
<ol><li>RVΔGL-Cre (on B19L-G_01 cells)</li></ol>	1.89E+05	1.99E+06	2.39E+06	1.76E+06	1.94E+06
(2) RVΔGL-Cre (on B19L-G_01 cells)	1.48E+05	1.97E+06	2.46E+06	1.77E+06	1.92E+06
(3) RV∆GL-Cre (on B19L-G_01 cells)	1.55E+05	1.89E+06	2.25E+06	1.55E+06	1.73E+06
(7) RV∆L-Cre (on B19L_02 cells)	8.60E+05	1.84E+07	2.60E+07	2.71E+07	2.10E+07
(8) RV∆L-Cre (on B19L_02 cells)	7.05E+05	1.35E+07	2.11E+07	2.54E+07	1.92E+07
(9) RV∆L-Cre (on B19L_02 cells)	1.17E+06	1.65E+07	2.25E+07	2.56E+07	1.70E+07
(13) RVΔL-Cre (on B19L-G_01 cells)	1.31E+06	1.92E+07	2.02E+07	1.87E+07	1.79E+07
(14) RV∆L-Cre (on B19L-G_01 cells)	1.88E+06	1.96E+07	1.92E+07	1.67E+07	1.79E+07
(15) RVΔL-Cre (on B19L-G_01 cells)	1.61E+06	1.89E+07	1.94E+07	1.51E+07	1.70E+07
(19) RV∆G-Cre (on B19G3-2 cells)	2.13E+06	3.12E+07	3.22E+07	3.02E+07	2.71E+07
(20) RV∆G-Cre (on B19G3-2 cells)	1.89E+06	3.22E+07	3.24E+07	2.63E+07	2.92E+07
(21) RV∆G-Cre (on B19G3-2 cells)	1.39E+06	2.19E+07	2.64E+07	2.01E+07	2.35E+07
(25) RV∆G-Cre (on B19L-G_01 cells)	1.71E+05	2.04E+06	1.14E+07	1.36E+07	1.37E+07
(26) RV∆G-Cre (on B19L-G_01 cells)	1.84E+05	2.40E+06	1.09E+07	1.18E+07	1.36E+07
(27) RV∆G-Cre (on B19L-G_01 cells)	1.65E+05	2.01E+06	9.61E+06	1.02E+07	1.14E+07
ACS data from Multi-step growth curves (Infectious units/mL)	24hr	48hr	72hr	96hr	120hr
(4) RV∆GL-Cre (on B19L-G_01 cells)	6.22E+03	4.36E+04	5.17E+05	7.09E+05	1.21E+06
(F) D)(AC) Cra (an D10) C 01 anlla)					
(5) RV∆GL-Cre (on B19L-G_01 cells)	7.77E+03	4.39E+04	4.47E+05	7.78E+05	9.81E+05
(5) RVΔGL-Cre (on B19L-G_01 cells) (6) RVΔGL-Cre (on B19L-G_01 cells)	7.77E+03 5.91E+03	4.39E+04 6.31E+04	4.47E+05 4.30E+05	7.78E+05 6.82E+05	9.81E+05 9.70E+05
., ,					
(6) RVΔGL-Cre (on B19L-G_01 cells)	5.91E+03	6.31E+04	4.30E+05	6.82E+05	9.70E+05
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells)	5.91E+03 6.84E+03	6.31E+04 5.48E+05	4.30E+05 5.50E+06	6.82E+05 9.25E+06	9.70E+05 1.26E+07
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells)	5.91E+03 6.84E+03 5.28E+03	6.31E+04 5.48E+05 2.96E+05	4.30E+05 5.50E+06 4.67E+06	6.82E+05 9.25E+06 9.18E+06	9.70E+05 1.26E+07 1.34E+07
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells) (12) RVΔL-Cre (on B19L_02 cells)	5.91E+03 6.84E+03 5.28E+03 5.59E+03	6.31E+04 5.48E+05 2.96E+05 6.57E+05	4.30E+05 5.50E+06 4.67E+06 6.63E+06	6.82E+05 9.25E+06 9.18E+06 1.07E+07	9.70E+05 1.26E+07 1.34E+07 1.34E+07
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells) (12) RVΔL-Cre (on B19L_02 cells) (16) RVΔL-Cre (on B19L-G_01 cells)	5.91E+03 6.84E+03 5.28E+03 5.59E+03 8.71E+03	6.31E+04 5.48E+05 2.96E+05 6.57E+05 1.31E+06	4.30E+05 5.50E+06 4.67E+06 6.63E+06 7.69E+06	6.82E+05 9.25E+06 9.18E+06 1.07E+07 5.80E+06	9.70E+05 1.26E+07 1.34E+07 1.34E+07 6.84E+06
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells) (12) RVΔL-Cre (on B19L_02 cells) (16) RVΔL-Cre (on B19L-G_01 cells) (17) RVΔL-Cre (on B19L-G_01 cells)	5.91E+03 6.84E+03 5.28E+03 5.59E+03 8.71E+03 4.04E+03	6.31E+04 5.48E+05 2.96E+05 6.57E+05 1.31E+06 1.38E+06	4.30E+05 5.50E+06 4.67E+06 6.63E+06 7.69E+06 6.40E+06	6.82E+05 9.25E+06 9.18E+06 1.07E+07 5.80E+06 6.33E+06	9.70E+05 1.26E+07 1.34E+07 1.34E+07 6.84E+06 6.57E+06
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells) (12) RVΔL-Cre (on B19L_02 cells) (16) RVΔL-Cre (on B19L-G_01 cells) (17) RVΔL-Cre (on B19L-G_01 cells) (18) RVΔL-Cre (on B19L-G_01 cells)	5.91E+03 6.84E+03 5.28E+03 5.59E+03 8.71E+03 4.04E+03 5.91E+03	6.31E+04 5.48E+05 2.96E+05 6.57E+05 1.31E+06 1.38E+06 1.11E+06	4.30E+05 5.50E+06 4.67E+06 6.63E+06 7.69E+06 6.40E+06 5.39E+06	6.82E+05 9.25E+06 9.18E+06 1.07E+07 5.80E+06 6.33E+06 5.40E+06	9.70E+05 1.26E+07 1.34E+07 1.34E+07 6.84E+06 6.57E+06 6.11E+06
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells) (12) RVΔL-Cre (on B19L_02 cells) (16) RVΔL-Cre (on B19L-G_01 cells) (17) RVΔL-Cre (on B19L-G_01 cells) (18) RVΔL-Cre (on B19L-G_01 cells) (22) RVΔG-Cre (on B19G3-2 cells)	5.91E+03 6.84E+03 5.28E+03 5.59E+03 8.71E+03 4.04E+03 5.91E+03 3.31E+04	6.31E+04 5.48E+05 2.96E+05 6.57E+05 1.31E+06 1.38E+06 1.11E+06 1.70E+06	4.30E+05 5.50E+06 4.67E+06 6.63E+06 7.69E+06 6.40E+06 5.39E+06 7.96E+06	6.82E+05 9.25E+06 9.18E+06 1.07E+07 5.80E+06 6.33E+06 5.40E+06 8.63E+06	9.70E+05 1.26E+07 1.34E+07 6.84E+06 6.57E+06 6.11E+06 7.39E+06
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells) (12) RVΔL-Cre (on B19L_02 cells) (16) RVΔL-Cre (on B19L-G_01 cells) (17) RVΔL-Cre (on B19L-G_01 cells) (18) RVΔL-Cre (on B19G3-2 cells) (22) RVΔG-Cre (on B19G3-2 cells) (23) RVΔG-Cre (on B19G3-2 cells)	5.91E+03 6.84E+03 5.28E+03 5.59E+03 8.71E+03 4.04E+03 5.91E+03 3.31E+04 2.24E+04	6.31E+04 5.48E+05 2.96E+05 6.57E+05 1.31E+06 1.38E+06 1.11E+06 1.70E+06 6.82E+05	4.30E+05 5.50E+06 4.67E+06 6.63E+06 6.40E+06 5.39E+06 7.96E+06 4.13E+06	6.82E+05 9.25E+06 9.18E+06 1.07E+07 5.80E+06 6.33E+06 5.40E+06 8.63E+06 5.36E+06	9.70E+05 1.26E+07 1.34E+07 1.34E+07 6.84E+06 6.57E+06 6.11E+06 7.39E+06 4.99E+06
(6) RVΔGL-Cre (on B19L-G_01 cells) (10) RVΔL-Cre (on B19L_02 cells) (11) RVΔL-Cre (on B19L_02 cells) (12) RVΔL-Cre (on B19L_02 cells) (16) RVΔL-Cre (on B19L-G_01 cells) (17) RVΔL-Cre (on B19L-G_01 cells) (18) RVΔL-Cre (on B19L-G_01 cells) (22) RVΔG-Cre (on B19G3-2 cells) (23) RVΔG-Cre (on B19G3-2 cells) (24) RVΔG-Cre (on B19G3-2 cells)	5.91E+03 6.84E+03 5.28E+03 8.71E+03 4.04E+03 5.91E+03 3.31E+04 2.24E+04 2.43E+04	6.31E+04 5.48E+05 2.96E+05 6.57E+05 1.31E+06 1.38E+06 1.11E+06 1.70E+06 6.82E+05 8.56E+05	4.30E+05 5.50E+06 4.67E+06 6.63E+06 7.69E+06 6.40E+06 7.96E+06 4.13E+06 4.41E+06	6.82E+05 9.25E+06 9.18E+06 1.07E+07 5.80E+06 6.33E+06 5.40E+06 5.36E+06 6.52E+06	9.70E+05 1.26E+07 1.34E+07 1.34E+07 6.84E+06 6.57E+06 6.11E+06 7.39E+06 4.99E+06 5.61E+06

24hr	48hr	72hr	96hr	120hr
1.64E+05	1.95E+06	2.37E+06	1.69E+06	1.86E+06
9.12E+05	1.61E+07	2.32E+07	2.60E+07	1.91E+07
1.60E+06	1.92E+07	1.96E+07	1.68E+07	1.76E+07
1.81E+06	2.85E+07	3.03E+07	2.55E+07	2.66E+07
1.73E+05	2.15E+06	1.06E+07	1.19E+07	1.29E+07
24hr	48hr	72hr	96hr	120hr
1.27E+04	3.12E+04	6.11E+04	7.25E+04	6.73E+04
1.37E+05	1.42E+06	1.45E+06	5.43E+05	1.16E+06
1.64E+05	2.12E+05	3.21E+05	1.04E+06	3.02E+05
2.18E+05	3.29E+06	1.99E+06	2.94E+06	1.66E+06
5.71E+03	1.24E+05	5.38E+05	9.85E+05	7.57E+05
24br	48hr	72hr	96hr	120hr
29111			3011	12011
6.63E+03	5.02E+04	4.65E+05	7.23E+05	1.05E+06
	9.12E+05 1.60E+06 1.81E+06 1.73E+05 24hr 1.27E+04 1.37E+05 1.64E+05 2.18E+05 5.71E+03	1.64E+05         1.95E+06           9.12E+05         1.61E+07           1.60E+06         1.92E+07           1.81E+06         2.85E+07           1.73E+05         2.15E+06           24hr         48hr           1.27E+04         3.12E+04           1.37E+05         2.42E+06           1.64E+05         2.12E+05           2.18E+05         3.29E+06	1.64E+05         1.95E+06         2.37E+06           9.12E+05         1.61E+07         2.32E+07           1.60E+06         1.92E+07         1.96E+07           1.81E+06         2.85E+07         3.03E+07           1.73E+05         2.15E+06         1.06E+07           24hr         48hr         72hr           1.27E+04         3.12E+04         6.11E+04           1.37E+05         1.42E+06         1.45E+06           1.64E+05         2.12E+05         3.21E+05           2.18E+05         3.22E+06         1.99E+06           5.71E+03         1.24E+05         5.38E+05	1.64E+05         1.95E+06         2.37E+06         1.69E+06           9.12E+05         1.61E+07         2.32E+07         2.60E+07           1.60E+06         1.92E+07         1.96E+07         1.68E+07           1.81E+06         2.85E+07         3.03E+07         2.55E+07           1.73E+05         2.15E+06         1.06E+07         1.19E+07           24hr         48hr         72hr         96hr           1.27E+04         3.12E+04         6.11E+04         7.25E+04           1.37E+05         1.42E+06         1.45E+06         5.43E+05           1.64E+05         2.12E+03         3.21E+05         1.04E+06           2.18E+05         3.29E+06         1.99E+06         2.94E+06           5.71E+03         1.24E+05         5.38E+05         9.85E+05


Standard error of the mean for Multi-step growth curves	24hr	48hr	72hr	96hr	120hr
(28-30) RV∆G-Cre (on B19L-G_01 cells)	6.84E+03	4.57E+04	4.59E+05	1.72E+06	5.27E+06
(22-24) RV∆G-Cre (on B19G3-2 cells)	2.66E+04	1.08E+06	5.50E+06	6.83E+06	6.00E+06
(16-18) RV∆L-Cre (on B19L-G_01 cells)	6.22E+03	1.27E+06	6.49E+06	5.84E+06	6.51E+06
(10-12) RV∆L-Cre (on B19L_02 cells)	5.91E+03	5.00E+05	5.60E+06	9.72E+06	1.31E+07

Standard erfor of the mean for main step growth curves			/ ====	3011	120111
(4-6) RV∆GL-Cre (on B19L-G_01 cells)	5.78E+02	6.45E+03	2.69E+04	2.87E+04	7.74E+04
(10-12) RVΔL-Cre (on B19L_02 cells)	4.75E+02	1.07E+05	5.70E+05	5.06E+05	2.77E+05
(16-18) RVΔL-Cre (on B19L-G_01 cells)	1.36E+03	8.07E+04	6.63E+05	2.71E+05	2.13E+05
(22-24) RV∆G-Cre (on B19G3-2 cells)	3.28E+03	3.16E+05	1.23E+06	9.57E+05	7.18E+05
(28-30) RV∆G-Cre (on B19L-G_01 cells)	8.98E+02	8.87E+03	6.60E+04	2.80E+05	3.51E+05

Conditions with the highest average titers for Single-step growth curves	Infectious units/mL
(1-3) RV∆GL-Cre (on B19L-G_01 cells): 72hr	2.39E+06
	2.46E+06
	2.25E+06
(7-9) RVΔL-Cre (on B19L_02 cells): 96hr	2.71E+07
	2.54E+07
	2.56E+07
(19-21) RV∆G-Cre (on B19G3-2 cells): 72hr	3.22E+07
	3.24E+07
	2.64E+07

Conditions with the highest average titers for Multi-step growth curves	Infectious units/mL
(4-6) RVΔGL-Cre (on B19L-G_01 cells): 120hr	1.21E+06
	9.81E+05
	9.70E+05
(10-12) RV∆L-Cre (on B19L_02 cells): 120hr	1.26E+07
	1.34E+07
	1.34E+07
(22-24) RVΔG-Cre (on B19G3-2 cells): 96hr	8.63E+06
	5.36E+06
	6.52E+06

Column1	Column2
average "ti	iter" of BC-FLEX cells:
3.63E+03	
Individual E	3C-FLEX negative "titers"
NEG_01	5.28E+03
NEG_02	5.91E+03
NEG_03	3.11E+03
NEG_04	2.80E+03
NEG_05	2.17E+03
NEG_06	2.49E+03



795 796

### Figure S3. Retrograde targeting with third-generation ( $\Delta$ L) rabies virus expressing the tetracycline transactivator, Related to Figure 2

799 (A) Corticothalamic neurons retrogradely labeled by a  $\Delta L$  virus expressing tTA injected in the

somatosensory thalamus of Ai63 reporter mice (Daigle et al., 2018) (tdTomato driven by TRE-tight) 1 week

801 (left image) or 4 weeks (right image) prior to perfusion. Scale bar: 200 µm, applies to both images.

802 (B) Counts of total labeled cortical neurons across every sixth section (see Methods) of each mouse brain.

- Numbers are not significantly different between the two time points (single factor ANOVA, p = 0.772, n = 4 mice per group).
- 805
- 806

### 807 File S2. Cell counts and statistics for retrograde targeting experiments, Related to Figure 2

808

809 See following pages.

810

RVAGL-Flpo: 1 week       21021505LJ       10       5         RVAGL-Flpo: 1 week       21021505LJ       11       8         RVAGL-Flpo: 1 week       21021505LJ       12       9         RVAGL-Flpo: 1 week       21021505LJ       total:       22         RVAGL-Flpo: 1 week       21021506LJ       9       5         RVAGL-Flpo: 1 week       21021506LJ       9       5         RVAGL-Flpo: 1 week       21021506LJ       10       6         RVAGL-Flpo: 1 week       21021506LJ       11       4         RVAGL-Flpo: 1 week       21021506LJ       12       3         RVAGL-Flpo: 1 week       21021507LJ       5       1         RVAGL-Flpo: 1 week       21021507LJ       6       27         RVAGL-Flpo: 1 week       21021507LJ       7       29         RVAGL-Flpo: 1 week       21021507LJ       8       25         RVAGL-Flpo: 1 week       21021507LJ       9       20         RVAGL-Flpo: 1 week       21021507LJ       10       <	
RVAGL-Flpo: 1 week       21021505LJ       11       8         RVAGL-Flpo: 1 week       21021505LJ       12       9         RVAGL-Flpo: 1 week       21021505LJ       total:       22         RVAGL-Flpo: 1 week       21021506LJ       9       5         RVAGL-Flpo: 1 week       21021506LJ       9       5         RVAGL-Flpo: 1 week       21021506LJ       10       6         RVAGL-Flpo: 1 week       21021506LJ       11       4         RVAGL-Flpo: 1 week       21021506LJ       12       3         RVAGL-Flpo: 1 week       21021506LJ       12       3         RVAGL-Flpo: 1 week       21021506LJ       12       3         RVAGL-Flpo: 1 week       21021507LJ       5       1         RVAGL-Flpo: 1 week       21021507LJ       5       1         RVAGL-Flpo: 1 week       21021507LJ       7       29         RVAGL-Flpo: 1 week       21021507LJ       8       25         RVAGL-Flpo: 1 week       21021507LJ       9       20         RVAGL-Flpo: 1 week       21021507LJ       10       10         RVAGL-Flpo: 1 week       21021507LJ       10       10         RVAGL-Flpo: 1 week       21021507LJ       11	
RVAGL-Flpo: 1 week       21021505U       12       9         RVAGL-Flpo: 1 week       21021505U       total:       22         RVAGL-Flpo: 1 week       21021506U       9       5         RVAGL-Flpo: 1 week       21021506U       10       6         RVAGL-Flpo: 1 week       21021506U       10       6         RVAGL-Flpo: 1 week       21021506U       11       4         RVAGL-Flpo: 1 week       21021506U       12       3         RVAGL-Flpo: 1 week       21021506U       total:       18         RVAGL-Flpo: 1 week       21021507U       5       1         RVAGL-Flpo: 1 week       21021507U       6       27         RVAGL-Flpo: 1 week       21021507U       7       29         RVAGL-Flpo: 1 week       21021507U       8       25         RVAGL-Flpo: 1 week       21021507U       9       20         RVAGL-Flpo: 1 week       21021507U       9       20         RVAGL-Flpo: 1 week       21021507U       10       10         RVAGL-Flpo: 1 week       21021507U       10       10	
RVAGL-Flpo: 1 week       21021505LJ       total:       22         RVAGL-Flpo: 1 week       21021506LJ       9       5         RVAGL-Flpo: 1 week       21021506LJ       10       6         RVAGL-Flpo: 1 week       21021506LJ       11       4         RVAGL-Flpo: 1 week       21021506LJ       11       4         RVAGL-Flpo: 1 week       21021506LJ       12       3         RVAGL-Flpo: 1 week       21021506LJ       10       1         RVAGL-Flpo: 1 week       21021506LJ       10       1         RVAGL-Flpo: 1 week       21021507LJ       5       1         RVAGL-Flpo: 1 week       21021507LJ       6       27         RVAGL-Flpo: 1 week       21021507LJ       7       29         RVAGL-Flpo: 1 week       21021507LJ       8       25         RVAGL-Flpo: 1 week       21021507LJ       9       20         RVAGL-Flpo: 1 week       21021507LJ       10       10         RVAGL-Flpo: 1 week       21021507LJ       10       10         RVAGL-Flpo: 1 week       21021507LJ       11       4	
RVΔGL-Flpo: 1 week21021506U95RVΔGL-Flpo: 1 week21021506U106RVΔGL-Flpo: 1 week21021506U114RVΔGL-Flpo: 1 week21021506U123RVΔGL-Flpo: 1 week21021506Utotal:18RVΔGL-Flpo: 1 week21021507U51RVΔGL-Flpo: 1 week21021507U627RVΔGL-Flpo: 1 week21021507U729RVΔGL-Flpo: 1 week21021507U825RVΔGL-Flpo: 1 week21021507U920RVΔGL-Flpo: 1 week21021507U1010RVΔGL-Flpo: 1 week21021507U114	
RVΔGL-Flpo: 1 week21021506U106RVΔGL-Flpo: 1 week21021506U114RVΔGL-Flpo: 1 week21021506U123RVΔGL-Flpo: 1 week21021506Utotal:18RVΔGL-Flpo: 1 week21021507U51RVΔGL-Flpo: 1 week21021507U627RVΔGL-Flpo: 1 week21021507U729RVΔGL-Flpo: 1 week21021507U825RVΔGL-Flpo: 1 week21021507U920RVΔGL-Flpo: 1 week21021507U1010RVΔGL-Flpo: 1 week21021507U1010	
RVAGL-Flpo: 1 week       21021506U       11       4         RVAGL-Flpo: 1 week       21021506U       12       3         RVAGL-Flpo: 1 week       21021506U       total:       18         RVAGL-Flpo: 1 week       21021507U       5       1         RVAGL-Flpo: 1 week       21021507U       6       27         RVAGL-Flpo: 1 week       21021507U       7       29         RVAGL-Flpo: 1 week       21021507U       8       25         RVAGL-Flpo: 1 week       21021507U       9       20         RVAGL-Flpo: 1 week       21021507U       10       10         RVAGL-Flpo: 1 week       21021507U       10       10	
RVΔGL-Flpo: 1 week21021506U123RVΔGL-Flpo: 1 week21021506Utotal:18RVΔGL-Flpo: 1 week21021507U51RVΔGL-Flpo: 1 week21021507U627RVΔGL-Flpo: 1 week21021507U729RVΔGL-Flpo: 1 week21021507U825RVΔGL-Flpo: 1 week21021507U920RVΔGL-Flpo: 1 week21021507U1010RVΔGL-Flpo: 1 week21021507U114	
RVΔGL-Flpo: 1 week       21021506U       total:       18         RVΔGL-Flpo: 1 week       21021507U       5       1         RVΔGL-Flpo: 1 week       21021507U       6       27         RVΔGL-Flpo: 1 week       21021507U       7       29         RVΔGL-Flpo: 1 week       21021507U       8       25         RVΔGL-Flpo: 1 week       21021507U       9       20         RVΔGL-Flpo: 1 week       21021507U       10       10         RVΔGL-Flpo: 1 week       21021507U       11       4	
RVΔGL-Flpo: 1 week       21021507LJ       5       1         RVΔGL-Flpo: 1 week       21021507LJ       6       27         RVΔGL-Flpo: 1 week       21021507LJ       7       29         RVΔGL-Flpo: 1 week       21021507LJ       8       25         RVΔGL-Flpo: 1 week       21021507LJ       9       20         RVΔGL-Flpo: 1 week       21021507LJ       10       10         RVΔGL-Flpo: 1 week       21021507LJ       11       4	
RVΔGL-Flpo: 1 week       21021507LJ       6       27         RVΔGL-Flpo: 1 week       21021507LJ       7       29         RVΔGL-Flpo: 1 week       21021507LJ       8       25         RVΔGL-Flpo: 1 week       21021507LJ       9       20         RVΔGL-Flpo: 1 week       21021507LJ       10       10         RVΔGL-Flpo: 1 week       21021507LJ       11       4	
RVΔGL-Flpo: 1 week       21021507LJ       7       29         RVΔGL-Flpo: 1 week       21021507LJ       8       25         RVΔGL-Flpo: 1 week       21021507LJ       9       20         RVΔGL-Flpo: 1 week       21021507LJ       10       10         RVΔGL-Flpo: 1 week       21021507LJ       11       4	
RVΔGL-Flpo: 1 week         21021507LJ         8         25           RVΔGL-Flpo: 1 week         21021507LJ         9         20           RVΔGL-Flpo: 1 week         21021507LJ         10         10           RVΔGL-Flpo: 1 week         21021507LJ         11         4	
RVΔGL-Flpo: 1 week         21021507LJ         9         20           RVΔGL-Flpo: 1 week         21021507LJ         10         10           RVΔGL-Flpo: 1 week         21021507LJ         11         4	
RVΔGL-Flpo: 1 week         21021507LJ         10         10           RVΔGL-Flpo: 1 week         21021507LJ         11         4	
RVΔGL-Flpo: 1 week         21021507LJ         11         4	
•	
RVΔGL-Flpo: 1 week         21021507LJ         12         3	
RVΔGL-Flpo: 1 week 21021507LJ 13 2	
RVΔGL-Flpo: 1 week 21021507LJ total: 121	
RVΔGL-Flpo: 1 week 21021508LJ 11 1	
RVΔGL-Flpo: 1 week 21021508LJ 15 1	
RVΔGL-Flpo: 1 week 21021508LJ total: 2	
RVΔGL-Flpo: 1 week 21052505LJ 9 1	
RVΔGL-Flpo: 1 week 21052505LJ 10 5	
RVΔGL-Flpo: 1 week 21052505LJ 11 1	
RVΔGL-Flpo: 1 week         21052505LJ         total:         7	
RVΔGL-Flpo: 1 week 21052506LJ 11 4	
RVΔGL-Flpo: 1 week 21052506LJ 12 4	
RVΔGL-Flpo: 1 week 21052506LJ total: 8	
RVΔGL-Flpo: 1 week 21052507LJ 6 2	
RVΔGL-Flpo: 1 week 21052507LJ 7 20	
RVΔGL-Flpo: 1 week 21052507LJ 8 45	
RVΔGL-Flpo: 1 week 21052507LJ 9 26	
RVΔGL-Flpo: 1 week 21052507LJ 10 5	
RV∆GL-Flpo: 1 week 21052507LJ total: 98	
RVΔGL-Flpo: 1 week 21052508LJ 8 1	
RVΔGL-Flpo: 1 week 21052508LJ 10 1	
RVΔGL-Flpo: 1 week 21052508LJ 11 1	
RVΔGL-Flpo: 1 week         21052508LJ         12         1	
RVΔGL-Flpo: 1 week         21052508LJ         14         2	
RVΔGL-Flpo: 1 week         21052508LJ         total:         6	
RVΔL-Flpo: 1 week         21021805LJ         1         57	
RVΔL-Flpo: 1 week         21021805LJ         2         20	
RVΔL-Flpo: 1 week         21021805LJ         3         11	
RVΔL-Flpo: 1 week         21021805LJ         4         115	
RVΔL-Flpo: 1 week         21021805LJ         5         270	
RVΔL-Flpo: 1 week         21021805LJ         6         399	
RVΔL-Flpo: 1 week         21021805LJ         7         428	
RVΔL-Flpo: 1 week         21021805LJ         8         542	
RVΔL-Flpo: 1 week         21021805LJ         9         416	
RVΔL-Flpo: 1 week         21021805LJ         10         368	
RVΔL-Flpo: 1 week         21021805LJ         11         240	
RVΔL-Flpo: 1 week         21021805LJ         12         106	
RVΔL-Flpo: 1 week         21021805LJ         13         42	

DVAL Elege 1 wook	2102100511	14	52
RVΔL-Flpo: 1 week RVΔL-Flpo: 1 week	21021805LJ 21021805LJ	14	27
RVΔL-Flpo: 1 week	21021805	total:	3093
RVΔL-Flpo: 1 week	21021805LJ	1	1
RVΔL-Flpo: 1 week	21021806LJ	4	5
RVΔL-Flpo: 1 week	21021806LJ	5	3
RVΔL-Flpo: 1 week	21021806LJ	6	4
RVΔL-Flpo: 1 week	21021806LJ	7	16
RVΔL-Flpo: 1 week	21021806LJ	8	35
RVΔL-Flpo: 1 week	21021806LJ		93
RVΔL-Flpo: 1 week	21021806LJ	9 10	74
RVΔL-Flpo: 1 week	21021806LJ	10	40
RVΔL-Flpo: 1 week	21021806LJ	12	24
RVΔL-Flpo: 1 week	21021806LJ	12	11
RVΔL-Flpo: 1 week			7
RVΔL-Flpo: 1 week	21021806LJ 21021806LJ	14 15	7
RVΔL-Flpo: 1 week		-	
RVΔL-Flp0: 1 week	21021806LJ	total:	320
•	21021807LJ	5	1
RVAL-Flpo: 1 week	21021807	6 7	2
RVAL-Flpo: 1 week	21021807LJ	•	6
RVAL-Flpo: 1 week	21021807LJ	8 9	8
RVAL-Flpo: 1 week	21021807LJ		35
RVAL-Flpo: 1 week	21021807	10	64
RVAL-Flpo: 1 week	21021807	11	80
RVAL-Flpo: 1 week	21021807LJ	12	55
RVAL-Flpo: 1 week	21021807LJ	13	34
RVAL-Flpo: 1 week	21021807	14	13
RVAL-Flpo: 1 week	21021807	15	13
RVAL-Flpo: 1 week	21021807	total:	311
RVAL-Flpo: 1 week	21021808LJ	6 7	7 13
RVAL-Flpo: 1 week	21021808LJ 21021808LJ		48
RVAL-Flpo: 1 week		8	
RVAL-Flpo: 1 week	21021808LJ	9	74
RVΔL-Flpo: 1 week RVΔL-Flpo: 1 week	21021808LJ	10	57
•	21021808LJ	11	20
RVAL-Flpo: 1 week	21021808LJ	12	13
RVΔL-Flpo: 1 week RVΔL-Flpo: 1 week	21021808LJ 21021808LJ	13	13
RVΔL-Flpo: 1 week	21021808LJ	14 15	14 4
· · · · · · · · · · · · · · · · · · ·			
RVΔL-Flpo: 1 week RVΔL-Flpo: 1 week	21021808LJ 21052607LJ	total: 4	263 3
RVΔL-Flpo: 1 week	21052607LJ	5	2
•			
RVAL-Flpo: 1 week	21052607LJ	6	4
RVAL-Flpo: 1 week	21052607LJ	7 o	11
RVΔL-Flpo: 1 week RVΔL-Flpo: 1 week	21052607LJ	8	10
•	21052607LJ	9	4
RVAL-Flpo: 1 week	21052607LJ	11	6 7
RVAL-Flpo: 1 week	21052607LJ	12	
RVAL-Flpo: 1 week	21052607LJ	total:	47
RVAL-Flpo: 1 week	21052608LJ	1	105
RVAL-Flpo: 1 week	21052608LJ	2	116
RVAL-Flpo: 1 week	21052608LJ	3	110
RVAL-Flpo: 1 week	21052608LJ	4	192
RVAL-Flpo: 1 week	21052608LJ	5	395
RVΔL-Flpo: 1 week	21052608LJ	6	389

	0405060011	-	
RVAL-Flpo: 1 week	21052608LJ	7	421
RVAL-Flpo: 1 week	21052608LJ	8	340
RVAL-Flpo: 1 week	21052608LJ	9	72
RVΔL-Flpo: 1 week	21052608LJ	10	14
RVΔL-Flpo: 1 week	21052608LJ	11	5
RVΔL-Flpo: 1 week	21052608LJ	12	2
RVΔL-Flpo: 1 week	21052608LJ	total:	2161
RVΔL-Flpo: 1 week	21060302LJ	1	8
RVΔL-Flpo: 1 week	21060302LJ	2	10
RVΔL-Flpo: 1 week	21060302LJ	3	17
RVΔL-Flpo: 1 week	21060302LJ	4	24
RVΔL-Flpo: 1 week	21060302LJ	5	22
RV∆L-Flpo: 1 week	21060302LJ	6	29
RVAL-Flpo: 1 week	21060302LJ	7	34
RVAL-Flpo: 1 week	21060302LJ	8	59
RVAL-Flpo: 1 week	21060302LJ	9	78
RVΔL-Flpo: 1 week	21060302LJ	10	46
RVΔL-Flpo: 1 week	21060302LJ	11	16
RVΔL-Flpo: 1 week	21060302LJ	12	12
RVAL-Flpo: 1 week	21060302LJ	13	6
RVΔL-Flpo: 1 week	21060302LJ	14	2
RVΔL-Flpo: 1 week	21060302LJ	15	2
RVAL-Flpo: 1 week	21060302LJ	total:	365
RVAL-Flpo: 1 week	21060303LJ	1	7
RVAL-Flpo: 1 week	21060303LJ	2	9
RVAL-Flpo: 1 week	21060303LJ	3	10
RVΔL-Flpo: 1 week	21060303LJ	4	16
RVΔL-Flpo: 1 week	21060303LJ	5	22
RVΔL-Flpo: 1 week	21060303LJ	6	27
RVΔL-Flpo: 1 week	21060303LJ	7	25
RVΔL-Flpo: 1 week	21060303LJ	8	27
RVΔL-Flpo: 1 week	21060303LJ	9	36
RVΔL-Flpo: 1 week	21060303LJ	10	30
RVΔL-Flpo: 1 week	21060303LJ	11	15
RVΔL-Flpo: 1 week	21060303LJ	12	7
RVΔL-Flpo: 1 week	21060303LJ	14	6
RVΔL-Flpo: 1 week	21060303LJ	15	1
RVAL-Flpo: 1 week	21060303LJ	total:	238
$RV\Delta GL$ -Flpo: 4 weeks	21021501LJ	7	2
RVΔGL-Flpo: 4 weeks	21021501LJ	8	12
RVΔGL-Flpo: 4 weeks	21021501	9	25
RVΔGL-Flpo: 4 weeks	21021501LJ	10	26
RVΔGL-Flpo: 4 weeks	21021501LJ	11	7
RVΔGL-FIpo: 4 weeks	21021501LJ	12	3
RVΔGL-FIpo: 4 weeks	21021501LJ	13	3
RVΔGL-FIpo: 4 weeks	21021501LJ	14	1
RVΔGL-FIpo: 4 weeks	21021501LJ	15	1
RVAGL-FIpo: 4 weeks	21021501LJ	total:	80
RVΔGL-Fipo: 4 weeks	21021501LJ 21021502LJ	9	2
•			
RVAGL-Flpo: 4 weeks	21021502LJ	10	25
RVAGL-Flpo: 4 weeks	21021502LJ	11	26
RVAGL-Flpo: 4 weeks	21021502LJ	12	5
RVAGL-Flpo: 4 weeks	21021502LJ	13	4
RVAGL-Flpo: 4 weeks	21021502LJ	total:	62
RVΔGL-Flpo: 4 weeks	21021503LJ	1	88

		-	
RVAGL-Flpo: 4 weeks	21021503LJ	2	129
RVAGL-Flpo: 4 weeks	21021503LJ	3	199
RVΔGL-Flpo: 4 weeks	21021503LJ	4	254
RVΔGL-Flpo: 4 weeks	21021503LJ	5	312
RV∆GL-Flpo: 4 weeks	21021503LJ	6	396
RV∆GL-Flpo: 4 weeks	21021503LJ	7	351
RV∆GL-Flpo: 4 weeks	21021503LJ	8	391
RV∆GL-Flpo: 4 weeks	21021503LJ	9	359
RV∆GL-Flpo: 4 weeks	21021503LJ	10	295
RV∆GL-Flpo: 4 weeks	21021503LJ	11	133
RV∆GL-Flpo: 4 weeks	21021503LJ	12	216
RVAGL-Flpo: 4 weeks	21021503LJ	13	59
RVΔGL-Flpo: 4 weeks	21021503LJ	14	40
RVAGL-Flpo: 4 weeks	21021503LJ	15	32
RVAGL-Flpo: 4 weeks	21021503LJ	total:	3254
RVAGL-Flpo: 4 weeks	21021504LJ	3	1
RVΔGL-Flpo: 4 weeks	21021504LJ	4	4
RV∆GL-Flpo: 4 weeks	21021504LJ	5	22
RVAGL-Flpo: 4 weeks	21021504LJ	6	24
RVΔGL-Flpo: 4 weeks	21021504LJ	7	56
RVΔGL-Flpo: 4 weeks	21021504LJ	8	78
RVΔGL-Flpo: 4 weeks	21021504LJ	9	32
RVΔGL-Flpo: 4 weeks	21021504LJ	10	18
RVΔGL-Flpo: 4 weeks	21021504LJ	11	1
RVΔGL-Flpo: 4 weeks	21021504LJ	12	1
RVΔGL-Flpo: 4 weeks	21021504LJ	total:	237
RVAGL-Flpo: 4 weeks	2102150415	2	1
RVAGL-Flpo: 4 weeks	21052501LJ	4	1
RVAGL-Flpo: 4 weeks	21052501	7	2
RVΔGL-Flpo: 4 weeks	21052501LJ	8	6
RVAGL-FIpo: 4 weeks	21052501LJ	9	9
RVAGL-Flpo: 4 weeks	21052501LJ	9 10	9
RVΔGL-Flpo: 4 weeks	21052501LJ	10	2
RVΔGL-Flpo: 4 weeks	21052501LJ		
•		12	6
RVAGL-Flpo: 4 weeks	21052501LJ	13	4
RVAGL-Flpo: 4 weeks	21052501LJ	14	1
RVAGL-Flpo: 4 weeks	21052501	15	2
RVAGL-Flpo: 4 weeks	21052501	total:	43
RVAGL-Flpo: 4 weeks	21052502	6	2
RVAGL-Flpo: 4 weeks	21052502LJ	7	1
RVAGL-Flpo: 4 weeks	21052502LJ	8	4
RVAGL-Flpo: 4 weeks	21052502	11	1
RVAGL-Flpo: 4 weeks	21052502LJ	14	3
RVΔGL-Flpo: 4 weeks	21052502LJ	15	3
RVΔGL-Flpo: 4 weeks	21052502LJ	total:	14
RV∆GL-Flpo: 4 weeks	21052503LJ	6	2
RVΔGL-Flpo: 4 weeks	21052503LJ	8	1
RV∆GL-Flpo: 4 weeks	21052503LJ	9	9
RV∆GL-Flpo: 4 weeks	21052503LJ	10	45
RV∆GL-Flpo: 4 weeks	21052503LJ	11	33
RV∆GL-Flpo: 4 weeks	21052503LJ	12	17
RV∆GL-Flpo: 4 weeks	21052503LJ	13	10
RV∆GL-Flpo: 4 weeks	21052503LJ	14	7
RVΔGL-Flpo: 4 weeks	21052503LJ	15	6
RVΔGL-Flpo: 4 weeks	21052503LJ	total:	130

		_	-
RVAGL-Flpo: 4 weeks	21052504LJ	7	2
RVΔGL-Flpo: 4 weeks	21052504LJ	8	13
RVΔGL-Flpo: 4 weeks	21052504LJ	9	18
RV∆GL-Flpo: 4 weeks	21052504LJ	10	16
RV∆GL-Flpo: 4 weeks	21052504LJ	11	8
RV∆GL-Flpo: 4 weeks	21052504LJ	12	3
RV∆GL-Flpo: 4 weeks	21052504LJ	13	3
RV∆GL-Flpo: 4 weeks	21052504LJ	14	1
RV∆GL-Flpo: 4 weeks	21052504LJ	15	1
RV∆GL-Flpo: 4 weeks	21052504LJ	total:	65
RV∆L-Flpo: 4 weeks	21021801LJ	1	36
RVΔL-Flpo: 4 weeks	21021801LJ	2	18
RVΔL-Flpo: 4 weeks	21021801LJ	3	2
RVΔL-Flpo: 4 weeks	21021801LJ	4	28
RVΔL-Flpo: 4 weeks	21021801LJ	5	180
RVΔL-Flpo: 4 weeks	21021801LJ	6	415
RVΔL-Flpo: 4 weeks	21021801LJ	7	622
RVΔL-Flpo: 4 weeks	21021801LJ	8	649
RVΔL-Flpo: 4 weeks	21021801LJ	9	739
RVΔL-Flpo: 4 weeks	21021801LJ	10	577
RVΔL-Flpo: 4 weeks	21021801LJ	11	431
RVΔL-Flpo: 4 weeks	21021801LJ	12	211
RVΔL-Flpo: 4 weeks	21021801LJ	13	166
RVΔL-Flpo: 4 weeks	21021801LJ	14	170
RVΔL-Flpo: 4 weeks	21021801LJ	15	370
RVΔL-Flpo: 4 weeks	21021801LJ	total:	4614
RVΔL-Flpo: 4 weeks	21021802LJ	1	3
RVΔL-Flpo: 4 weeks	21021802LJ	2	6
RVΔL-Flpo: 4 weeks	21021802LJ	3	8
RVΔL-Flpo: 4 weeks	21021802LJ	5	32
RVΔL-Flpo: 4 weeks	21021802LJ	6	224
RVΔL-Flpo: 4 weeks	21021802LJ	7	279
RVΔL-Flpo: 4 weeks	21021802LJ	8	287
RVΔL-Flpo: 4 weeks	21021802LJ	9	457
RVΔL-Flpo: 4 weeks	21021802LJ	10	501
RVΔL-Flpo: 4 weeks	21021802LJ	11	491
RVΔL-Flpo: 4 weeks	21021802LJ	12	211
RVΔL-Flpo: 4 weeks	21021802LJ	13	287
RVΔL-Flpo: 4 weeks	21021802LJ	14	220
RVAL-Flpo: 4 weeks	21021802LJ	total:	3006
RVAL-Flpo: 4 weeks	21021802LJ	2	6
RVAL-Flpo: 4 weeks	21021803	3	9
RVΔL-Flpo: 4 weeks	21021803		48
		4	
RVAL-Flpo: 4 weeks	21021803LJ	5	177
RVAL-Flpo: 4 weeks	21021803LJ	6	247
RVAL-Flpo: 4 weeks	21021803LJ	7	339
RVAL-Flpo: 4 weeks	21021803LJ	8	316
RVAL-Flpo: 4 weeks	21021803LJ	9	322
RVAL-Flpo: 4 weeks	21021803LJ	10	205
RVAL-Flpo: 4 weeks	21021803LJ	11	78
RVAL-Flpo: 4 weeks	21021803LJ	12	46
RVΔL-Flpo: 4 weeks	21021803LJ	13	41
		A	n 1
RVAL-Flpo: 4 weeks	21021803LJ	14	13
RVΔL-Flpo: 4 weeks RVΔL-Flpo: 4 weeks RVΔL-Flpo: 4 weeks	21021803LJ 21021803LJ 21021804LJ	14 total: 1	13 1847 6

RVAL-Fipo: 4 weeks       21021804LJ       2       14         RVAL-Fipo: 4 weeks       21021804LJ       3       2         RVAL-Fipo: 4 weeks       21021804LJ       5       359         RVAL-Fipo: 4 weeks       21021804LJ       6       414         RVAL-Fipo: 4 weeks       21021804LJ       7       469         RVAL-Fipo: 4 weeks       21021804LJ       8       576         RVAL-Fipo: 4 weeks       21021804LJ       9       533         RVAL-Fipo: 4 weeks       21021804LJ       10       383         RVAL-Fipo: 4 weeks       21021804LJ       11       283         RVAL-Fipo: 4 weeks       21021804LJ       13       34         RVAL-Fipo: 4 weeks       21021804LJ       13       34         RVAL-Fipo: 4 weeks       21021804LJ       13       34         RVAL-Fipo: 4 weeks       21021804LJ       13       31         RVAL-Fipo: 4 weeks       21021804LJ       12       1         RVAL-Fipo: 4 weeks       21021804LJ       13       14         RVAL-Fipo: 4 weeks       21052601LJ       2       1         RVAL-Fipo: 4 weeks       21052601LJ       10       12         RVAL-Fipo: 4 weeks       21052601LJ       10 </th <th></th>	
RVAL-Fipo: 4 weeks         21021804U         4         57           RVAL-Fipo: 4 weeks         21021804U         5         359           RVAL-Fipo: 4 weeks         21021804U         7         469           RVAL-Fipo: 4 weeks         21021804U         8         576           RVAL-Fipo: 4 weeks         21021804U         8         576           RVAL-Fipo: 4 weeks         21021804U         10         383           RVAL-Fipo: 4 weeks         21021804U         11         283           RVAL-Fipo: 4 weeks         21021804U         12         114           RVAL-Fipo: 4 weeks         21021804U         13         34           RVAL-Fipo: 4 weeks         21021804U         14         87           RVAL-Fipo: 4 weeks         21052601U         2         1           RVAL-Fipo: 4 weeks         21052601U         3         1           RVAL-Fipo: 4 weeks         21052601U         10	
RVAL-Fipo: 4 weeks         21021804U         5         359           RVAL-Fipo: 4 weeks         21021804U         6         414           RVAL-Fipo: 4 weeks         21021804U         8         576           RVAL-Fipo: 4 weeks         21021804U         9         533           RVAL-Fipo: 4 weeks         21021804U         9         533           RVAL-Fipo: 4 weeks         21021804U         10         383           RVAL-Fipo: 4 weeks         21021804U         11         283           RVAL-Fipo: 4 weeks         21021804U         12         114           RVAL-Fipo: 4 weeks         21021804U         14         87           RVAL-Fipo: 4 weeks         21021804U         14         87           RVAL-Fipo: 4 weeks         21052601U         2         1           RVAL-Fipo: 4 weeks         21052601U         3         1           RVAL-Fipo: 4 weeks         21052601U         5         16           RVAL-Fipo: 4 weeks         21052601U         7         28           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         11         280           RVAL-Fipo: 4 weeks         21052601U         12	
RVAL-Flp:         4 weeks         21021804U         6         414           RVAL-Flp:         4 weeks         21021804U         7         469           RVAL-Flp:         4 weeks         21021804U         9         533           RVAL-Flp:         4 weeks         21021804U         9         533           RVAL-Flp:         4 weeks         21021804U         10         383           RVAL-Flp:         4 weeks         21021804U         11         283           RVAL-Flp:         4 weeks         21021804U         13         34           RVAL-Flp:         4 weeks         21021804U         14         87           RVAL-Flp:         4 weeks         21021804U         14         87           RVAL-Flp:         4 weeks         21052601U         2         1           RVAL-Flp:         4 weeks         21052601U         3         1           RVAL-Flp:         4 weeks         21052601U         6         10           RVAL-Flp:         4 weeks         21052601U         7         28           RVAL-Flp:         4 weeks         21052601U         10         232           RVAL-Flp:         4 weeks         21052601U         11	
RVAL-Fipo: 4 weeks     21021804U     7     469       RVAL-Fipo: 4 weeks     21021804U     8     576       RVAL-Fipo: 4 weeks     21021804U     9     533       RVAL-Fipo: 4 weeks     21021804U     10     383       RVAL-Fipo: 4 weeks     21021804U     12     114       RVAL-Fipo: 4 weeks     21021804U     13     34       RVAL-Fipo: 4 weeks     21021804U     14     87       RVAL-Fipo: 4 weeks     21021804U     10al:     3331       RVAL-Fipo: 4 weeks     2105201U     2     1       RVAL-Fipo: 4 weeks     2105201U     5     16       RVAL-Fipo: 4 weeks     2105201U     5     16       RVAL-Fipo: 4 weeks     2105201U     7     28       RVAL-Fipo: 4 weeks     2105201U     8     92       RVAL-Fipo: 4 weeks     2105201U     10     232       RVAL-Fipo: 4 weeks     2105201U     11     280       RVAL-Fipo: 4 weeks     2105201U     11     280       RVAL-Fipo: 4 weeks     2105201U     12     201       RVAL-Fipo: 4 weeks     2105201U     14     106       RVAL-Fipo: 4 weeks     2105201U     14     369       RVAL-Fipo: 4 weeks     2105201U     14     369	
RVAL-Fipo: 4 weeks     21021804U     8     576       RVAL-Fipo: 4 weeks     21021804U     9     533       RVAL-Fipo: 4 weeks     21021804U     10     383       RVAL-Fipo: 4 weeks     21021804U     11     283       RVAL-Fipo: 4 weeks     21021804U     12     114       RVAL-Fipo: 4 weeks     21021804U     13     34       RVAL-Fipo: 4 weeks     21021804U     14     87       RVAL-Fipo: 4 weeks     21021804U     14     87       RVAL-Fipo: 4 weeks     21052601U     3     1       RVAL-Fipo: 4 weeks     21052601U     5     16       RVAL-Fipo: 4 weeks     21052601U     7     28       RVAL-Fipo: 4 weeks     21052601U     7     28       RVAL-Fipo: 4 weeks     21052601U     7     28       RVAL-Fipo: 4 weeks     21052601U     10     232       RVAL-Fipo: 4 weeks     21052601U     11     280       RVAL-Fipo: 4 weeks     21052601U     13     143       RVAL-Fipo: 4 weeks     21052601U     13     143       RVAL-Fipo: 4 weeks     21052601U     14     106       RVAL-Fipo: 4 weeks     21052601U     14     106       RVAL-Fipo: 4 weeks     21052602U     1     149	
RVAL-Fipo: 4 weeks         21021804U         9         533           RVAL-Fipo: 4 weeks         21021804U         10         383           RVAL-Fipo: 4 weeks         21021804U         11         283           RVAL-Fipo: 4 weeks         21021804U         12         114           RVAL-Fipo: 4 weeks         21021804U         13         34           RVAL-Fipo: 4 weeks         21021804U         14         87           RVAL-Fipo: 4 weeks         21052601U         2         1           RVAL-Fipo: 4 weeks         21052601U         3         1           RVAL-Fipo: 4 weeks         21052601U         5         16           RVAL-Fipo: 4 weeks         21052601U         6         10           RVAL-Fipo: 4 weeks         21052601U         8         92           RVAL-Fipo: 4 weeks         21052601U         8         92           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         11         280           RVAL-Fipo: 4 weeks         21052601U         13         143           RVAL-Fipo: 4 weeks         21052601U         14         106           RVAL-Fipo: 4 weeks         21052601U         14	
RVAL-Fipo: 4 weeks         21021804U         10         383           RVAL-Fipo: 4 weeks         21021804U         12         114           RVAL-Fipo: 4 weeks         21021804U         13         34           RVAL-Fipo: 4 weeks         21021804U         13         34           RVAL-Fipo: 4 weeks         21021804U         14         87           RVAL-Fipo: 4 weeks         21021804U         10         3331           RVAL-Fipo: 4 weeks         21052601U         2         1           RVAL-Fipo: 4 weeks         21052601U         3         1           RVAL-Fipo: 4 weeks         21052601U         6         10           RVAL-Fipo: 4 weeks         21052601U         6         10           RVAL-Fipo: 4 weeks         21052601U         8         92           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         13         143           RVAL-Fipo: 4 weeks         21052601U         14         106           RVAL-Fipo: 4 weeks         21052601U         14         106           RVAL-Fipo: 4 weeks         21052602U         1	
RVAL-Fipo: 4 weeks         21021804U         11         283           RVAL-Fipo: 4 weeks         21021804U         13         34           RVAL-Fipo: 4 weeks         21021804U         14         87           RVAL-Fipo: 4 weeks         21021804U         14         87           RVAL-Fipo: 4 weeks         21021804U         total:         3331           RVAL-Fipo: 4 weeks         21052601U         3         1           RVAL-Fipo: 4 weeks         21052601U         5         16           RVAL-Fipo: 4 weeks         21052601U         5         16           RVAL-Fipo: 4 weeks         21052601U         7         28           RVAL-Fipo: 4 weeks         21052601U         8         92           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         11         280           RVAL-Fipo: 4 weeks         21052601U         12         201           RVAL-Fipo: 4 weeks         21052601U         13         143           RVAL-Fipo: 4 weeks         21052601U         13         143           RVAL-Fipo: 4 weeks         21052601U         14         106           RVAL-Fipo: 4 weeks         21052601U         1	
RVAL-Fipo: 4 weeks         21021804U         12         114           RVAL-Fipo: 4 weeks         21021804U         13         34           RVAL-Fipo: 4 weeks         21021804U         144         87           RVAL-Fipo: 4 weeks         21021804U         1ctal:         3331           RVAL-Fipo: 4 weeks         21052601U         2         1           RVAL-Fipo: 4 weeks         21052601U         5         16           RVAL-Fipo: 4 weeks         21052601U         5         16           RVAL-Fipo: 4 weeks         21052601U         6         10           RVAL-Fipo: 4 weeks         21052601U         7         28           RVAL-Fipo: 4 weeks         21052601U         8         92           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         12         201           RVAL-Fipo: 4 weeks         21052601U         13         143           RVAL-Fipo: 4 weeks         21052601U         14         106           RVAL-Fipo: 4 weeks         21052601U         15         98           RVAL-Fipo: 4 weeks         21052601U         12	
RVAL-Fipo: 4 weeks       21021804U       13       34         RVAL-Fipo: 4 weeks       21021804U       1d       87         RVAL-Fipo: 4 weeks       210221804U       1d1       3331         RVAL-Fipo: 4 weeks       21052601U       2       1         RVAL-Fipo: 4 weeks       21052601U       3       1         RVAL-Fipo: 4 weeks       21052601U       5       16         RVAL-Fipo: 4 weeks       21052601U       6       10         RVAL-Fipo: 4 weeks       21052601U       7       28         RVAL-Fipo: 4 weeks       21052601U       9       161         RVAL-Fipo: 4 weeks       21052601U       10       232         RVAL-Fipo: 4 weeks       21052601U       10       232         RVAL-Fipo: 4 weeks       21052601U       11       280         RVAL-Fipo: 4 weeks       21052601U       11       280         RVAL-Fipo: 4 weeks       21052601U       12       201         RVAL-Fipo: 4 weeks       21052601U       14       106         RVAL-Fipo: 4 weeks       21052601U       15       98         RVAL-Fipo: 4 weeks       21052602U       1       49         RVAL-Fipo: 4 weeks       21052602U       10 <t< td=""><td></td></t<>	
RVAL-Fipo: 4 weeks       21021804U       14       87         RVAL-Fipo: 4 weeks       21021804U       total:       3331         RVAL-Fipo: 4 weeks       21052601U       3       1         RVAL-Fipo: 4 weeks       21052601U       5       16         RVAL-Fipo: 4 weeks       21052601U       6       10         RVAL-Fipo: 4 weeks       21052601U       6       10         RVAL-Fipo: 4 weeks       21052601U       8       92         RVAL-Fipo: 4 weeks       21052601U       9       161         RVAL-Fipo: 4 weeks       21052601U       9       161         RVAL-Fipo: 4 weeks       21052601U       10       232         RVAL-Fipo: 4 weeks       21052601U       10       232         RVAL-Fipo: 4 weeks       21052601U       11       280         RVAL-Fipo: 4 weeks       21052601U       13       143         RVAL-Fipo: 4 weeks       21052601U       14       106         RVAL-Fipo: 4 weeks       21052601U       14       106         RVAL-Fipo: 4 weeks       21052601U       14       106         RVAL-Fipo: 4 weeks       21052601U       10       13         RVAL-Fipo: 4 weeks       21052602U       163	
RVAL-Fipo: 4 weeks         21021804U         total:         3331           RVAL-Fipo: 4 weeks         21052601U         2         1           RVAL-Fipo: 4 weeks         21052601U         5         16           RVAL-Fipo: 4 weeks         21052601U         6         10           RVAL-Fipo: 4 weeks         21052601U         6         10           RVAL-Fipo: 4 weeks         21052601U         7         28           RVAL-Fipo: 4 weeks         21052601U         9         161           RVAL-Fipo: 4 weeks         21052601U         9         161           RVAL-Fipo: 4 weeks         21052601U         10         232           RVAL-Fipo: 4 weeks         21052601U         12         201           RVAL-Fipo: 4 weeks         21052601U         13         143           RVAL-Fipo: 4 weeks         21052601U         14         106           RVAL-Fipo: 4 weeks         21052601U         14         106           RVAL-Fipo: 4 weeks         21052601U         13         13           RVAL-Fipo: 4 weeks         21052601U         14         16           RVAL-Fipo: 4 weeks         21052601U         10         12           RVAL-Fipo: 4 weeks         21052602U         12<	
RVAL-Flpo: 4 weeks         210526011         2         1           RVAL-Flpo: 4 weeks         210526011         3         1           RVAL-Flpo: 4 weeks         210526011         5         16           RVAL-Flpo: 4 weeks         210526011         6         10           RVAL-Flpo: 4 weeks         210526011         7         28           RVAL-Flpo: 4 weeks         210526011         9         161           RVAL-Flpo: 4 weeks         210526011         9         161           RVAL-Flpo: 4 weeks         210526011         10         232           RVAL-Flpo: 4 weeks         210526011         11         280           RVAL-Flpo: 4 weeks         210526011         12         201           RVAL-Flpo: 4 weeks         210526011         13         143           RVAL-Flpo: 4 weeks         210526011         14         106           RVAL-Flpo: 4 weeks         210526011         15         98           RVAL-Flpo: 4 weeks         210526011         14         106           RVAL-Flpo: 4 weeks         210526011         14         106           RVAL-Flpo: 4 weeks         210526011         15         163           RVAL-Flpo: 4 weeks         210526021         2	
RVAL-Flpo: 4 weeks       21052601U       3       1         RVAL-Flpo: 4 weeks       21052601U       5       16         RVAL-Flpo: 4 weeks       21052601U       6       10         RVAL-Flpo: 4 weeks       21052601U       7       28         RVAL-Flpo: 4 weeks       21052601U       9       161         RVAL-Flpo: 4 weeks       21052601U       9       161         RVAL-Flpo: 4 weeks       21052601U       10       232         RVAL-Flpo: 4 weeks       21052601U       10       232         RVAL-Flpo: 4 weeks       21052601U       11       280         RVAL-Flpo: 4 weeks       21052601U       12       201         RVAL-Flpo: 4 weeks       21052601U       13       143         RVAL-Flpo: 4 weeks       21052601U       14       106         RVAL-Flpo: 4 weeks       21052601U       15       98         RVAL-Flpo: 4 weeks       21052601U       14       9         RVAL-Flpo: 4 weeks       21052602U       1       49         RVAL-Flpo: 4 weeks       21052602U       3       17         RVAL-Flpo: 4 weeks       21052602U       3       17         RVAL-Flpo: 4 weeks       21052602U       6       418<	
RVAL-Flpo: 4 weeks         2105260111         5         16           RVAL-Flpo: 4 weeks         2105260111         6         10           RVAL-Flpo: 4 weeks         2105260111         7         28           RVAL-Flpo: 4 weeks         2105260111         8         92           RVAL-Flpo: 4 weeks         2105260111         9         161           RVAL-Flpo: 4 weeks         2105260111         10         232           RVAL-Flpo: 4 weeks         2105260111         11         280           RVAL-Flpo: 4 weeks         2105260111         12         201           RVAL-Flpo: 4 weeks         2105260111         14         106           RVAL-Flpo: 4 weeks         2105260111         14         106           RVAL-Flpo: 4 weeks         2105260111         14         106           RVAL-Flpo: 4 weeks         2105260111         15         98           RVAL-Flpo: 4 weeks         2105260111         14         94           RVAL-Flpo: 4 weeks         2105260111         14         94           RVAL-Flpo: 4 weeks         2105260211         14         15           RVAL-Flpo: 4 weeks         2105260211         12         12           RVAL-Flpo: 4 weeks         2105260211	
RVAL-Flpo: 4 weeks         21052601U         6         10           RVAL-Flpo: 4 weeks         21052601U         7         28           RVAL-Flpo: 4 weeks         21052601U         8         92           RVAL-Flpo: 4 weeks         21052601U         9         161           RVAL-Flpo: 4 weeks         21052601U         10         232           RVAL-Flpo: 4 weeks         21052601U         11         280           RVAL-Flpo: 4 weeks         21052601U         12         201           RVAL-Flpo: 4 weeks         21052601U         13         143           RVAL-Flpo: 4 weeks         21052601U         13         143           RVAL-Flpo: 4 weeks         21052601U         14         106           RVAL-Flpo: 4 weeks         21052601U         15         98           RVAL-Flpo: 4 weeks         21052601U         14         161           RVAL-Flpo: 4 weeks         21052601U         14         161           RVAL-Flpo: 4 weeks         21052601U         10         139           RVAL-Flpo: 4 weeks         21052602U         1         49           RVAL-Flpo: 4 weeks         21052602U         163         163           RVAL-Flpo: 4 weeks         21052602U         1	
RVAL-Flpo: 4 weeks         21052601U         7         28           RVAL-Flpo: 4 weeks         21052601U         8         92           RVAL-Flpo: 4 weeks         21052601U         9         161           RVAL-Flpo: 4 weeks         21052601U         9         161           RVAL-Flpo: 4 weeks         21052601U         10         232           RVAL-Flpo: 4 weeks         21052601U         11         280           RVAL-Flpo: 4 weeks         21052601U         12         201           RVAL-Flpo: 4 weeks         21052601U         13         143           RVAL-Flpo: 4 weeks         21052601U         14         106           RVAL-Flpo: 4 weeks         21052601U         15         98           RVAL-Flpo: 4 weeks         21052601U         14         106           RVAL-Flpo: 4 weeks         21052602U         1         49           RVAL-Flpo: 4 weeks         21052602U         12         12           RVAL-Flpo: 4 weeks         21052602U         12         12           RVAL-Flpo: 4 weeks         21052602U         163         17           RVAL-Flpo: 4 weeks         21052602U         163         163           RVAL-Flpo: 4 weeks         21052602U         16	
RVAL-Flpo: 4 weeks         21052601U         8         92           RVAL-Flpo: 4 weeks         21052601U         9         161           RVAL-Flpo: 4 weeks         21052601U         10         232           RVAL-Flpo: 4 weeks         21052601U         10         232           RVAL-Flpo: 4 weeks         21052601U         11         280           RVAL-Flpo: 4 weeks         21052601U         12         201           RVAL-Flpo: 4 weeks         21052601U         13         143           RVAL-Flpo: 4 weeks         21052601U         14         106           RVAL-Flpo: 4 weeks         21052602U         1         49           RVAL-Flpo: 4 weeks         21052602U         2         12           RVAL-Flpo: 4 weeks         21052602U         3         17           RVAL-Flpo: 4 weeks         21052602U         5         163           RVAL-Flpo: 4 weeks         21052602U         5         163           RVAL-Flpo: 4 weeks         21052602U         8 </td <td></td>	
RVAL-Flpo: 4 weeks       21052601LJ       9       161         RVAL-Flpo: 4 weeks       21052601LJ       10       232         RVAL-Flpo: 4 weeks       21052601LJ       11       280         RVAL-Flpo: 4 weeks       21052601LJ       12       201         RVAL-Flpo: 4 weeks       21052601LJ       13       143         RVAL-Flpo: 4 weeks       21052601LJ       14       106         RVAL-Flpo: 4 weeks       21052601LJ       15       98         RVAL-Flpo: 4 weeks       21052601LJ       15       98         RVAL-Flpo: 4 weeks       21052601LJ       14       106         RVAL-Flpo: 4 weeks       21052601LJ       14       94         RVAL-Flpo: 4 weeks       21052602LJ       1       49         RVAL-Flpo: 4 weeks       21052602LJ       2       12         RVAL-Flpo: 4 weeks       21052602LJ       3       17         RVAL-Flpo: 4 weeks       21052602LJ       5       163         RVAL-Flpo: 4 weeks       21052602LJ       5       163         RVAL-Flpo: 4 weeks       21052602LJ       6       418         RVAL-Flpo: 4 weeks       21052602LJ       8       526         RVAL-Flpo: 4 weeks       21052602LJ       <	
RVAL-Flpo: 4 weeks       21052601LJ       10       232         RVAL-Flpo: 4 weeks       21052601LJ       11       280         RVAL-Flpo: 4 weeks       21052601LJ       12       201         RVAL-Flpo: 4 weeks       21052601LJ       13       143         RVAL-Flpo: 4 weeks       21052601LJ       13       143         RVAL-Flpo: 4 weeks       21052601LJ       14       106         RVAL-Flpo: 4 weeks       21052601LJ       15       98         RVAL-Flpo: 4 weeks       21052601LJ       total:       1369         RVAL-Flpo: 4 weeks       21052602LJ       2       12         RVAL-Flpo: 4 weeks       21052602LJ       2       12         RVAL-Flpo: 4 weeks       21052602LJ       3       17         RVAL-Flpo: 4 weeks       21052602LJ       3       17         RVAL-Flpo: 4 weeks       21052602LJ       5       163         RVAL-Flpo: 4 weeks       21052602LJ       5       163         RVAL-Flpo: 4 weeks       21052602LJ       7       489         RVAL-Flpo: 4 weeks       21052602LJ       8       526         RVAL-Flpo: 4 weeks       21052602LJ       10       319         RVAL-Flpo: 4 weeks       21052602LJ	
RVΔL-Flpo: 4 weeks       21052601J       11       280         RVΔL-Flpo: 4 weeks       21052601J       12       201         RVΔL-Flpo: 4 weeks       21052601J       13       143         RVΔL-Flpo: 4 weeks       21052601J       14       106         RVΔL-Flpo: 4 weeks       21052601J       14       106         RVΔL-Flpo: 4 weeks       21052601J       15       98         RVΔL-Flpo: 4 weeks       21052601J       104       49         RVΔL-Flpo: 4 weeks       21052602J       1       49         RVΔL-Flpo: 4 weeks       21052602J       2       12         RVΔL-Flpo: 4 weeks       21052602J       3       17         RVΔL-Flpo: 4 weeks       21052602J       3       17         RVΔL-Flpo: 4 weeks       21052602J       4       51         RVΔL-Flpo: 4 weeks       21052602J       5       163         RVΔL-Flpo: 4 weeks       21052602J       6       418         RVΔL-Flpo: 4 weeks       21052602J       7       489         RVΔL-Flpo: 4 weeks       21052602J       9       510         RVΔL-Flpo: 4 weeks       21052602J       10       319         RVΔL-Flpo: 4 weeks       21052602J       10       <	
RVAL-Fipo: 4 weeks       21052601LJ       12       201         RVAL-Fipo: 4 weeks       21052601LJ       13       143         RVAL-Fipo: 4 weeks       21052601LJ       14       106         RVAL-Fipo: 4 weeks       21052601LJ       15       98         RVAL-Fipo: 4 weeks       21052601LJ       total:       1369         RVAL-Fipo: 4 weeks       21052602LJ       1       49         RVAL-Fipo: 4 weeks       21052602LJ       2       12         RVAL-Fipo: 4 weeks       21052602LJ       3       17         RVAL-Fipo: 4 weeks       21052602LJ       3       17         RVAL-Fipo: 4 weeks       21052602LJ       4       51         RVAL-Fipo: 4 weeks       21052602LJ       5       163         RVAL-Fipo: 4 weeks       21052602LJ       5       163         RVAL-Fipo: 4 weeks       21052602LJ       6       418         RVAL-Fipo: 4 weeks       21052602LJ       7       489         RVAL-Fipo: 4 weeks       21052602LJ       9       510         RVAL-Fipo: 4 weeks       21052602LJ       10       319         RVAL-Fipo: 4 weeks       21052602LJ       11       179         RVAL-Fipo: 4 weeks       21052602LJ	
RVAL-Fipo: 4 weeks       21052601L       13       143         RVAL-Fipo: 4 weeks       21052601L       14       106         RVAL-Fipo: 4 weeks       21052601L       15       98         RVAL-Fipo: 4 weeks       21052601L       10tal:       1369         RVAL-Fipo: 4 weeks       21052602L       1       49         RVAL-Fipo: 4 weeks       21052602L       2       12         RVAL-Fipo: 4 weeks       21052602L       3       17         RVAL-Fipo: 4 weeks       21052602L       3       17         RVAL-Fipo: 4 weeks       21052602L       4       51         RVAL-Fipo: 4 weeks       21052602L       5       163         RVAL-Fipo: 4 weeks       21052602L       6       418         RVAL-Fipo: 4 weeks       21052602L       7       489         RVAL-Fipo: 4 weeks       21052602L       8       526         RVAL-Fipo: 4 weeks       21052602L       10       319         RVAL-Fipo: 4 weeks       21052602L       11       179         RVAL-Fipo: 4 weeks       21052602L       12       72         RVAL-Fipo: 4 weeks       21052602L       13       48         RVAL-Fipo: 4 weeks       21052602L       13	
RVΔL-Flpo: 4 weeks21052601L14106RVΔL-Flpo: 4 weeks21052601L1598RVΔL-Flpo: 4 weeks21052601Ltotal:1369RVΔL-Flpo: 4 weeks21052602L149RVΔL-Flpo: 4 weeks21052602L212RVΔL-Flpo: 4 weeks21052602L317RVΔL-Flpo: 4 weeks21052602L317RVΔL-Flpo: 4 weeks21052602L451RVΔL-Flpo: 4 weeks21052602L5163RVΔL-Flpo: 4 weeks21052602L6418RVΔL-Flpo: 4 weeks21052602L7489RVΔL-Flpo: 4 weeks21052602L8526RVΔL-Flpo: 4 weeks21052602L9510RVΔL-Flpo: 4 weeks21052602L10319RVΔL-Flpo: 4 weeks21052602L11179RVΔL-Flpo: 4 weeks21052602L1272RVΔL-Flpo: 4 weeks21052602L1348RVΔL-Flpo: 4 weeks21052602L1432RVΔL-Flpo: 4 weeks21052602L1534	
RVΔL-Flpo: 4 weeks21052601LJ1598RVΔL-Flpo: 4 weeks21052602LJtotal:1369RVΔL-Flpo: 4 weeks21052602LJ149RVΔL-Flpo: 4 weeks21052602LJ212RVΔL-Flpo: 4 weeks21052602LJ317RVΔL-Flpo: 4 weeks21052602LJ451RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	-
RVΔL-Flpo: 4 weeks21052601LJ1598RVΔL-Flpo: 4 weeks21052602LJtotal:1369RVΔL-Flpo: 4 weeks21052602LJ149RVΔL-Flpo: 4 weeks21052602LJ212RVΔL-Flpo: 4 weeks21052602LJ317RVΔL-Flpo: 4 weeks21052602LJ451RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052601LJtotal:1369RVΔL-Flpo: 4 weeks21052602LJ149RVΔL-Flpo: 4 weeks21052602LJ212RVΔL-Flpo: 4 weeks21052602LJ317RVΔL-Flpo: 4 weeks21052602LJ451RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ149RVΔL-Flpo: 4 weeks21052602LJ212RVΔL-Flpo: 4 weeks21052602LJ317RVΔL-Flpo: 4 weeks21052602LJ451RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ212RVΔL-Flpo: 4 weeks21052602LJ317RVΔL-Flpo: 4 weeks21052602LJ451RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ317RVΔL-Flpo: 4 weeks21052602LJ451RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ451RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ5163RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1332RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ6418RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ7489RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ8526RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ9510RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ10319RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks21052602LJ11179RVΔL-Flpo: 4 weeks21052602LJ1272RVΔL-Flpo: 4 weeks21052602LJ1348RVΔL-Flpo: 4 weeks21052602LJ1432RVΔL-Flpo: 4 weeks21052602LJ1534	
RVΔL-Flpo: 4 weeks       21052602LJ       12       72         RVΔL-Flpo: 4 weeks       21052602LJ       13       48         RVΔL-Flpo: 4 weeks       21052602LJ       14       32         RVΔL-Flpo: 4 weeks       21052602LJ       15       34	
RVΔL-Flpo: 4 weeks         21052602LJ         13         48           RVΔL-Flpo: 4 weeks         21052602LJ         14         32           RVΔL-Flpo: 4 weeks         21052602LJ         15         34	
RVΔL-Flpo: 4 weeks         21052602LJ         14         32           RVΔL-Flpo: 4 weeks         21052602LJ         15         34	
RVΔL-Flpo: 4 weeks         21052602LJ         15         34	
RVAL-Flpo: 4 weeks         21052603LJ         1         38           DVAL Flags 4 weeks         21052603LJ         2         22	
RVAL-Flpo: 4 weeks         21052603LJ         2         33	
RVAL-Flpo: 4 weeks         21052603LJ         3         16	
RVΔL-Flpo: 4 weeks         21052603LJ         4         44	
RVΔL-Flpo: 4 weeks         21052603LJ         5         302	
RVΔL-Flpo: 4 weeks         21052603LJ         6         648	
RVΔL-Flpo: 4 weeks         21052603LJ         7         636	
RVΔL-Flpo: 4 weeks 21052603LJ 8 666	
RVΔL-Flpo: 4 weeks         21052603LJ         9         582	
RVΔL-Flpo: 4 weeks         21052603LJ         10         409	
RVΔL-Flpo: 4 weeks         21052603LJ         11         207	

RVAL-Flpo: 4 weeks	21052603LJ	12	79
RVΔL-Flpo: 4 weeks	21052603LJ	13	26
RVΔL-Flpo: 4 weeks	21052603LJ	14	25
RVΔL-Flpo: 4 weeks	21052603LJ	15	19
RVAL-Flpo: 4 weeks	21052603LJ	total:	3730
RVAL-Flpo: 4 weeks	21052606LJ	1	43
RVAL-Flpo: 4 weeks	21052606	2	23
RVAL-Flpo: 4 weeks	21052606LJ	3	14
RVAL-Flpo: 4 weeks	21052606LJ	4	32
RVΔL-Flpo: 4 weeks			
RVΔL-FIp0: 4 weeks RVΔL-FIp0: 4 weeks	21052606LJ	5	220
	21052606LJ	6	503
RVAL-Flpo: 4 weeks	21052606LJ	7	616
RVAL-Flpo: 4 weeks	21052606LJ	8	622
RVAL-Flpo: 4 weeks	21052606LJ	9	560
RVAL-Flpo: 4 weeks	21052606LJ	10	403
RVAL-Flpo: 4 weeks	21052606LJ	11	179
RVAL-Flpo: 4 weeks	21052606LJ	12	82
RVAL-Flpo: 4 weeks	21052606LJ	13	56
RVAL-Flpo: 4 weeks	21052606LJ	14	68
RVΔL-Flpo: 4 weeks	21052606LJ	15	33
RVΔL-Flpo: 4 weeks	21052606LJ	total:	3454
RVΔGL-Cre: 1 week	21021703LJ	1	422
RVΔGL-Cre: 1 week	21021703LJ	2	395
RV∆GL-Cre: 1 week	21021703LJ	3	606
RV∆GL-Cre: 1 week	21021703LJ	4	543
RV∆GL-Cre: 1 week	21021703	5	637
RV∆GL-Cre: 1 week	21021703LJ	6	848
RV∆GL-Cre: 1 week	21021703LJ	7	1145
RVΔGL-Cre: 1 week	21021703LJ	8	1183
RVΔGL-Cre: 1 week	21021703LJ	9	1292
RVΔGL-Cre: 1 week	21021703LJ	10	1311
RVΔGL-Cre: 1 week	21021703LJ	11	1377
RVAGL-Cre: 1 week	21021703LJ	12	1251
RVAGL-Cre: 1 week	21021703LJ	13	998
RVAGL-Cre: 1 week	21021703LJ	14	835
RVAGL-Cre: 1 week	21021703LJ	15	641
RVAGL-Cre: 1 week	21021703LJ	total:	13484
RVAGL-Cre: 1 week	21021704LJ	1	918
RVAGL-Cre: 1 week	21021704LJ	2	975
RVAGL-Cre: 1 week	21021704LJ	3	1144
RVAGL-Cre: 1 week	21021704LJ	4	1404
RVAGL-Cre: 1 week	21021704LJ	5	1491
RVAGL-Cre: 1 week	21021704LJ	6	1377
RVΔGL-Cre: 1 week	21021704LJ	7	1231
RVAGL-Cre: 1 week	21021704LJ	8	1337
RVΔGL-Cre: 1 week	21021704LJ	9	1135
RV∆GL-Cre: 1 week	21021704LJ	10	1058
RVAGL-Cre: 1 week	21021704LJ	11	711
RVAGL-Cre: 1 week	21021704LJ	12	568
RVAGL-Cre: 1 week	21021704LJ	13	443
RVΔGL-Cre: 1 week	21021704LJ	14	432
RVAGL-Cre: 1 week	21021704LJ	15	411
RVAGL-Cre: 1 week	21021704LJ	total:	14635
RVAGL-Cre: 1 week	21021704	1	497
RVΔGL-Cre: 1 week	21021707LJ	2	568

DVACL Creed week	2402470711	2	45.4
RVΔGL-Cre: 1 week RVΔGL-Cre: 1 week	21021707LJ 21021707LJ	3	454 454
RVΔGL-Cre: 1 week	21021707LJ		583
		5	
RVAGL-Cre: 1 week	21021707LJ	6	873
RVAGL-Cre: 1 week	21021707LJ	7	973
RVAGL-Cre: 1 week	21021707LJ	8	1133
RVAGL-Cre: 1 week	21021707LJ	9	1220
RVAGL-Cre: 1 week	21021707	10	1176
RVΔGL-Cre: 1 week	21021707LJ	11	994
RVΔGL-Cre: 1 week	21021707	12	645
RVΔGL-Cre: 1 week	21021707LJ	13	467
RVΔGL-Cre: 1 week	21021707LJ	14	330
RVΔGL-Cre: 1 week	21021707LJ	15	280
RVΔGL-Cre: 1 week	21021707	total:	10647
RVΔGL-Cre: 1 week	21021708LJ	1	271
RVΔGL-Cre: 1 week	21021708LJ	2	303
RVΔGL-Cre: 1 week	21021708LJ	3	386
RVΔGL-Cre: 1 week	21021708LJ	4	634
RV∆GL-Cre: 1 week	21021708LJ	5	805
RV∆GL-Cre: 1 week	21021708LJ	6	931
RV∆GL-Cre: 1 week	21021708LJ	7	1029
RV∆GL-Cre: 1 week	21021708LJ	8	1186
RV∆GL-Cre: 1 week	21021708LJ	9	1227
RV∆GL-Cre: 1 week	21021708LJ	10	1102
RV∆GL-Cre: 1 week	21021708LJ	11	1019
RV∆GL-Cre: 1 week	21021708LJ	12	666
RV∆GL-Cre: 1 week	21021708LJ	13	431
RV∆GL-Cre: 1 week	21021708LJ	14	369
RV∆GL-Cre: 1 week	21021708LJ	15	486
RV∆GL-Cre: 1 week	21021708LJ	total:	10845
RVΔL-Cre: 1 week	21021905LJ	1	1161
RVΔL-Cre: 1 week	21021905LJ	2	1093
RVAL-Cre: 1 week	21021905LJ	3	1072
RV∆L-Cre: 1 week	21021905LJ	4	1079
RVAL-Cre: 1 week	21021905LJ	5	1318
RV∆L-Cre: 1 week	21021905LJ	6	1417
RVΔL-Cre: 1 week	21021905LJ	7	1541
RVΔL-Cre: 1 week	21021905LJ	8	1510
RVΔL-Cre: 1 week	21021905LJ	9	1500
RVΔL-Cre: 1 week	21021905LJ	10	1549
RVΔL-Cre: 1 week	21021905LJ	11	1381
RVΔL-Cre: 1 week	21021905LJ	12	1109
RVΔL-Cre: 1 week	21021905LJ	13	532
RVΔL-Cre: 1 week	21021905LJ	14	380
RVΔL-Cre: 1 week	21021905LJ	15	265
RVΔL-Cre: 1 week	21021905LJ	total:	16907
RVΔL-Cre: 1 week	21021906LJ	1	985
RV∆L-Cre: 1 week	21021906LJ	2	1012
RVΔL-Cre: 1 week	21021906LJ	3	1020
RVΔL-Cre: 1 week	21021906LJ	4	1060
RVΔL-Cre: 1 week	21021906LJ	5	1082
RVΔL-Cre: 1 week	21021906LJ	6	1515
RVΔL-Cre: 1 week	21021906LJ	7	1808
RVΔL-Cre: 1 week	21021906LJ	8	1675
RVΔL-Cre: 1 week	21021906LJ	9	1538
	10119000	•	

RVAL-Cre: 1 week	21021906LJ	10	1728
RVΔL-Cre: 1 week	21021906LJ	11	955
RVΔL-Cre: 1 week	21021906LJ	12	1018
RVΔL-Cre: 1 week	21021906LJ	13	993
RVΔL-Cre: 1 week	21021906LJ	14	701
RVΔL-Cre: 1 week	21021906LJ	15	483
RVΔL-Cre: 1 week	21021906LJ	16	350
RV∆L-Cre: 1 week	21021906LJ	total:	17923
RVΔL-Cre: 1 week	21021907	1	1207
RV∆L-Cre: 1 week	21021907LJ	2	1083
RV∆L-Cre: 1 week	21021907LJ	3	1152
RV∆L-Cre: 1 week	21021907LJ	4	1225
RVΔL-Cre: 1 week	21021907LJ	5	1336
RVΔL-Cre: 1 week	21021907LJ	6	1558
RVΔL-Cre: 1 week	21021907LJ	7	1498
RVΔL-Cre: 1 week	21021907LJ	8	1709
RVΔL-Cre: 1 week	21021907LJ	9	1547
RV∆L-Cre: 1 week	21021907LJ	10	1718
RV∆L-Cre: 1 week	21021907LJ	11	1503
RVΔL-Cre: 1 week	21021907LJ	12	1249
RV∆L-Cre: 1 week	21021907LJ	13	845
RVΔL-Cre: 1 week	21021907LJ	14	626
RVΔL-Cre: 1 week	21021907LJ	15	495
RVΔL-Cre: 1 week	21021907LJ	total:	18751
RVΔL-Cre: 1 week	21021908LJ	1	1011
RVΔL-Cre: 1 week	21021908LJ	2	892
RVΔL-Cre: 1 week	21021908LJ	3	896
RVΔL-Cre: 1 week	21021908LJ	4	957
RVΔL-Cre: 1 week	21021908LJ	5	1243
RVΔL-Cre: 1 week	21021908LJ	6	1448
RV∆L-Cre: 1 week	21021908LJ	7	1568
RVΔL-Cre: 1 week	21021908LJ	8	1459
RV∆L-Cre: 1 week	21021908LJ	9	1573
RVΔL-Cre: 1 week	21021908LJ	10	1313
RV∆L-Cre: 1 week	21021908LJ	11	1146
RVΔL-Cre: 1 week	21021908LJ	12	1046
RVΔL-Cre: 1 week	21021908LJ	13	774
RVΔL-Cre: 1 week	21021908LJ	14	483
RV∆L-Cre: 1 week	21021908LJ	15	448
RVΔL-Cre: 1 week	21021908LJ	total:	16257
RV∆GL-Cre: 4 weeks	21021701LJ	1	1314
RV∆GL-Cre: 4 weeks	21021701	2	1246
RV∆GL-Cre: 4 weeks	21021701LJ	3	1351
RV∆GL-Cre: 4 weeks	21021701LJ	4	1601
RV∆GL-Cre: 4 weeks	21021701LJ	5	1668
RV∆GL-Cre: 4 weeks	21021701	6	1618
RV∆GL-Cre: 4 weeks	21021701LJ	7	1593
RV∆GL-Cre: 4 weeks	21021701	8	1757
RV∆GL-Cre: 4 weeks	21021701	9	1730
RV∆GL-Cre: 4 weeks	21021701LJ	10	1600
RV∆GL-Cre: 4 weeks	21021701	11	1268
RV∆GL-Cre: 4 weeks	21021701LJ	12	931
RV∆GL-Cre: 4 weeks	21021701LJ	13	652
RV∆GL-Cre: 4 weeks	21021701LJ	14	491
RV∆GL-Cre: 4 weeks	21021701LJ	15	336

	2402470411		10150
RVAGL-Cre: 4 weeks	21021701LJ	total:	19156
RVAGL-Cre: 4 weeks	21021702LJ	1	957
RVAGL-Cre: 4 weeks	21021702LJ	2	1175
RVAGL-Cre: 4 weeks	21021702LJ	3	1414
RVAGL-Cre: 4 weeks	21021702LJ	4	1470
RVΔGL-Cre: 4 weeks	21021702LJ	5	1481
RVΔGL-Cre: 4 weeks	21021702LJ	6	1654
RVΔGL-Cre: 4 weeks	21021702LJ	7	1616
RVΔGL-Cre: 4 weeks	21021702LJ	8	1601
RVΔGL-Cre: 4 weeks	21021702LJ	9	1717
RVΔGL-Cre: 4 weeks	21021702LJ	10	1449
RV∆GL-Cre: 4 weeks	21021702LJ	11	1132
RVAGL-Cre: 4 weeks	21021702LJ	12	871
RVAGL-Cre: 4 weeks	21021702LJ	13	587
RV∆GL-Cre: 4 weeks	21021702LJ	14	456
RVAGL-Cre: 4 weeks	21021702LJ	15	355
RV∆GL-Cre: 4 weeks	21021702LJ	total:	17935
RV∆GL-Cre: 4 weeks	21021705LJ	1	892
RV∆GL-Cre: 4 weeks	21021705LJ	2	824
RVΔGL-Cre: 4 weeks	21021705LJ	3	879
RV∆GL-Cre: 4 weeks	21021705LJ	4	1094
RV∆GL-Cre: 4 weeks	21021705LJ	5	1182
RVAGL-Cre: 4 weeks	21021705LJ	6	1318
RVAGL-Cre: 4 weeks	21021705LJ	7	1482
RV∆GL-Cre: 4 weeks	21021705LJ	8	1637
RVAGL-Cre: 4 weeks	21021705LJ	9	1666
RV∆GL-Cre: 4 weeks	21021705LJ	10	1796
RVAGL-Cre: 4 weeks	21021705LJ	11	1636
RV∆GL-Cre: 4 weeks	21021705LJ	12	1415
RV∆GL-Cre: 4 weeks	21021705LJ	13	1121
RV∆GL-Cre: 4 weeks	21021705LJ	14	894
RVAGL-Cre: 4 weeks	21021705LJ	15	703
RVAGL-Cre: 4 weeks	21021705LJ	total:	18539
RVAGL-Cre: 4 weeks	21021706LJ	1	756
RVAGL-Cre: 4 weeks	21021706LJ	2	817
RVAGL-Cre: 4 weeks	21021706LJ	3	750
RVAGL-Cre: 4 weeks	21021706LJ	4	798
RVAGL-Cre: 4 weeks	21021706LJ	5	920
RVAGL-Cre: 4 weeks	21021706LJ	6	1337
$RV\Delta GL-Cre: 4$ weeks	21021706LJ	7	1485
$RV\Delta GL-Cre: 4$ weeks	21021706LJ	8	1490
RVΔGL-Cre: 4 weeks	21021706LJ	9	1641
RVΔGL-Cre: 4 weeks	21021706LJ	10	2004
RVAGL-Cre: 4 weeks	21021706LJ	11	1955
RVAGL-Cre: 4 weeks	21021706LJ	12	1453
RVAGL-Cre: 4 weeks	21021706LJ	13	1455
RVAGL-Cre: 4 weeks	21021706LJ	14	769
RVΔGL-Cre: 4 weeks	21021706LJ	14	641
RVAGL-Cre: 4 weeks	21021706LJ	total:	17938
RVΔL-Cre: 4 weeks	21021708LJ 21021901LJ		943
RVΔL-Cre: 4 weeks	21021901LJ	1 2	1003
RVΔL-Cre: 4 weeks			
	21021901LJ	3	1036
RVAL-Cre: 4 weeks	21021901LJ	4	1195
RVAL-Cre: 4 weeks	21021901LJ	5	1402
RV∆L-Cre: 4 weeks	21021901LJ	6	1739

RVΔL-Cre: 4 weeks	21021901LJ	7	1793
RVΔL-Cre: 4 weeks	21021901LJ	8	1913
RVΔL-Cre: 4 weeks	21021901LJ	9	2026
RVAL-Cre: 4 weeks	21021901LJ	10	1913
RVAL-Cre: 4 weeks	21021901LJ	11	1929
RVAL-Cre: 4 weeks	21021901LJ	12	1668
RVAL-Cre: 4 weeks	21021901LJ	13	1247
RVΔL-Cre: 4 weeks	21021901LJ	14	1062
RVΔL-Cre: 4 weeks	21021901LJ	15	874
RVΔL-Cre: 4 weeks	21021901LJ	total:	21743
RVΔL-Cre: 4 weeks	21021902LJ	1	1357
RVΔL-Cre: 4 weeks	21021902LJ	2	1416
RV∆L-Cre: 4 weeks	21021902	3	1287
RV∆L-Cre: 4 weeks	21021902LJ	4	1308
RVΔL-Cre: 4 weeks	21021902LJ	5	1583
RVΔL-Cre: 4 weeks	21021902LJ	6	1850
RVΔL-Cre: 4 weeks	21021902LJ	7	2020
RVΔL-Cre: 4 weeks	21021902LJ	8	2238
RVΔL-Cre: 4 weeks	21021902LJ	9	2092
RV∆L-Cre: 4 weeks	21021902LJ	10	2321
RVΔL-Cre: 4 weeks	21021902LJ	11	2241
RVΔL-Cre: 4 weeks	21021902	12	1858
RVΔL-Cre: 4 weeks	21021902LJ	13	1326
RVΔL-Cre: 4 weeks	21021902LJ	14	1083
RVΔL-Cre: 4 weeks	21021902LJ	15	793
RVΔL-Cre: 4 weeks	21021902LJ	total:	24773
RVAL-Cre: 4 weeks	21021902LJ	1	1543
RVAL-Cre: 4 weeks	21021903LJ	2	1406
RVAL-Cre: 4 weeks	21021903	3	1303
RVΔL-Cre: 4 weeks	21021903	4	1489
RVΔL-Cre: 4 weeks	21021903LJ	5	1825
	21021903LJ		
RVAL-Cre: 4 weeks		6	1946
RVAL-Cre: 4 weeks	21021903LJ	7	1924
RVAL-Cre: 4 weeks	21021903LJ	8	2142
RVAL-Cre: 4 weeks	21021903LJ	9	2077
RVAL-Cre: 4 weeks	21021903LJ	10	1954
RVAL-Cre: 4 weeks	21021903LJ	11	1672
RVAL-Cre: 4 weeks	21021903LJ	12	1411
RVAL-Cre: 4 weeks	21021903LJ	13	1020
RVAL-Cre: 4 weeks	21021903LJ	14	687
RVΔL-Cre: 4 weeks	21021903LJ	15	627
RVΔL-Cre: 4 weeks	21021903LJ	total:	23026
RVΔL-Cre: 4 weeks	21021904LJ	1	1592
RVΔL-Cre: 4 weeks	21021904LJ	2	1466
RV∆L-Cre: 4 weeks	21021904LJ	3	1355
RVΔL-Cre: 4 weeks	21021904LJ	4	1599
RVΔL-Cre: 4 weeks	21021904LJ	5	1736
RVΔL-Cre: 4 weeks	21021904LJ	6	1862
RVΔL-Cre: 4 weeks	21021904LJ	7	1794
RVΔL-Cre: 4 weeks	21021904LJ	8	1930
RVΔL-Cre: 4 weeks	21021904LJ	9	2047
RV∆L-Cre: 4 weeks	21021904LJ	10	1584
RVΔL-Cre: 4 weeks	21021904LJ	11	1755
RVΔL-Cre: 4 weeks	21021904LJ	12	1431
RVΔL-Cre: 4 weeks	21021904LJ	13	741

RVΔL-Cre: 4 weeks	21021904LJ	14	755
RVΔL-Cre: 4 weeks	21021904LJ	14	625
RVAL-Cre: 4 weeks	21021904LJ	total:	22272
RVAL-5tTA: 1 week	21042901LJ	3	2
RVAL-5tTA: 1 week	21042901LJ	6	9
RVAL-5tTA: 1 week	21042901LJ	7	4
RVAL-5tTA: 1 week	21042901LJ	8	26
RVAL-5tTA: 1 week	21042901LJ	9	32
RVAL-5tTA: 1 week	21042901LJ	10	54
RVAL-5tTA: 1 week	21042901LJ	11	69
RVΔL-5tTA: 1 week	21042901LJ	12	56
RVΔL-5tTA: 1 week	21042901LJ	13	51
RVΔL-5tTA: 1 week	21042901LJ	14	14
RVΔL-5tTA: 1 week	21042901LJ	15	22
RVΔL-5tTA: 1 week	21042901LJ	total:	339
RVΔL-5tTA: 1 week	21042902LJ	1	4
RVΔL-5tTA: 1 week	21042902LJ	2	11
RVΔL-5tTA: 1 week	21042902LJ	3	14
RVΔL-5tTA: 1 week	21042902LJ	4	4
RVΔL-5tTA: 1 week	21042902LJ	5	39
RVΔL-5tTA: 1 week	21042902LJ	6	108
RVΔL-5tTA: 1 week	21042902LJ	7	213
RVΔL-5tTA: 1 week	21042902LJ	8	255
RVΔL-5tTA: 1 week	21042902LJ	9	296
RVΔL-5tTA: 1 week	21042902LJ	10	219
RVΔL-5tTA: 1 week	21042902LJ	11	134
RVΔL-5tTA: 1 week	21042902LJ	12	64
RVΔL-5tTA: 1 week	21042902LJ	13	29
RVΔL-5tTA: 1 week	21042902LJ	14	14
RVΔL-5tTA: 1 week	21042902LJ	15	7
RVΔL-5tTA: 1 week	21042902LJ	total:	1411
RVΔL-5tTA: 1 week	21042903LJ	2	3
RVΔL-5tTA: 1 week	21042903LJ	3	7
RVΔL-5tTA: 1 week	21042903LJ	4	6
RVΔL-5tTA: 1 week	21042903LJ	5	4
RVΔL-5tTA: 1 week	21042903LJ	6	27
RVΔL-5tTA: 1 week	21042903LJ	7	40
RVΔL-5tTA: 1 week	21042903LJ	8	81
RVΔL-5tTA: 1 week	21042903LJ	9	115
RVΔL-5tTA: 1 week	21042903LJ	10	165
RVΔL-5tTA: 1 week	21042903LJ	11	120
RVΔL-5tTA: 1 week	21042903LJ	12	84
RVΔL-5tTA: 1 week	21042903LJ	13	67
RVAL-5tTA: 1 week	21042903	14	44
RVAL-5tTA: 1 week	21042903LJ	15	33
RVAL-5tTA: 1 week	21042903	total:	796
RVAL-5tTA: 1 week	21042303LJ	1	85
RVAL-5tTA: 1 week	21060301LJ	2	117
RVΔL-5tTA: 1 week	21060301LJ	3	154
RVΔL-5tTA: 1 week	21060301LJ	4	59
$RV\Delta L-5TTA: 1 week$ RV $\Delta L-5tTA: 1 week$			207
	21060301LJ	5	
RVAL-5tTA: 1 week	21060301LJ	6	325
RVAL-5tTA: 1 week	21060301LJ	7	314
RVAL-5tTA: 1 week	21060301LJ	8	303
RVΔL-5tTA: 1 week	21060301LJ	9	288

RVΔL-5tTA: 1 week	21060301	10	185
RVΔL-5tTA: 1 week	21060301LJ	11	141
RVΔL-5tTA: 1 week	21060301LJ	12	47
RVΔL-5tTA: 1 week	21060301LJ	13	19
RVAL-5tTA: 1 week	21060301LJ	14	14
RVΔL-5tTA: 1 week	21060301LJ	15	13
RVΔL-5tTA: 1 week	21060301LJ	total:	2271
RVAL-5tTA: 4 weeks	21042905LJ	1	4
RVAL-5tTA: 4 weeks	21042905LJ	2	14
RVAL-5tTA: 4 weeks	21042905LJ	3	6
RVAL-5tTA: 4 weeks	21042905LJ	4	21
RVAL-5tTA: 4 weeks	21042905LJ	5	15
RVAL-5tTA: 4 weeks	21042905LJ	6	41
RVAL-5tTA: 4 weeks	21042905LJ	7	41 42
RVAL-5tTA: 4 weeks	21042905LJ	8	101
RVΔL-5tTA: 4 weeks	21042905LJ	9	156
	21042905LJ	-	
RVAL-5tTA: 4 weeks		10	109
RVAL-5tTA: 4 weeks	21042905LJ	11	94
RVAL-5tTA: 4 weeks	21042905LJ	12	24
RVAL-5tTA: 4 weeks	21042905LJ	13	87
RVAL-5tTA: 4 weeks	21042905LJ	14	44
RVAL-5tTA: 4 weeks	21042905LJ	15	71
RVAL-5tTA: 4 weeks	21042905LJ	total:	829
RVAL-5tTA: 4 weeks	21042906LJ	1	9
RVΔL-5tTA: 4 weeks	21042906LJ	2	17
RVΔL-5tTA: 4 weeks	21042906LJ	3	28
RVΔL-5tTA: 4 weeks	21042906LJ	4	23
RVΔL-5tTA: 4 weeks	21042906LJ	5	24
RVΔL-5tTA: 4 weeks	21042906LJ	6	25
RVΔL-5tTA: 4 weeks	21042906LJ	7	93
RVΔL-5tTA: 4 weeks	21042906LJ	8	200
RVΔL-5tTA: 4 weeks	21042906LJ	9	305
RVΔL-5tTA: 4 weeks	21042906LJ	10	233
RVΔL-5tTA: 4 weeks	21042906LJ	11	200
RVΔL-5tTA: 4 weeks	21042906LJ	12	141
RVΔL-5tTA: 4 weeks	21042906LJ	13	74
RVΔL-5tTA: 4 weeks	21042906LJ	14	108
RVΔL-5tTA: 4 weeks	21042906LJ	15	94
RVΔL-5tTA: 4 weeks	21042906LJ	total:	1574
RVΔL-5tTA: 4 weeks	21042907LJ	2	2
RVΔL-5tTA: 4 weeks	21042907LJ	4	3
RVΔL-5tTA: 4 weeks	21042907LJ	5	5
RVΔL-5tTA: 4 weeks	21042907LJ	6	24
RVΔL-5tTA: 4 weeks	21042907LJ	7	32
RVΔL-5tTA: 4 weeks	21042907LJ	8	51
RVΔL-5tTA: 4 weeks	21042907LJ	9	100
RVΔL-5tTA: 4 weeks	21042907LJ	10	74
RVΔL-5tTA: 4 weeks	21042907LJ	11	69
RVΔL-5tTA: 4 weeks	21042907LJ	12	54
RVΔL-5tTA: 4 weeks	21042907LJ	13	26
RVΔL-5tTA: 4 weeks	21042907LJ	14	31
RVΔL-5tTA: 4 weeks	21042907LJ	15	28
RV∆L-5tTA: 4 weeks	21042907LJ	total:	499
RV∆L-5tTA: 4 weeks	21042908LJ	1	64
RVΔL-5tTA: 4 weeks	21042908LJ	2	67

RVΔL-5tTA: 4 weeks	21042908LJ	3	66
RVΔL-5tTA: 4 weeks	21042908LJ	4	79
RVΔL-5tTA: 4 weeks	21042908LJ	5	151
RVΔL-5tTA: 4 weeks	21042908LJ	6	149
RVΔL-5tTA: 4 weeks	21042908LJ	7	166
RVΔL-5tTA: 4 weeks	21042908LJ	8	171
RVΔL-5tTA: 4 weeks	21042908LJ	9	184
RVΔL-5tTA: 4 weeks	21042908LJ	10	57
RVΔL-5tTA: 4 weeks	21042908LJ	11	48
RVΔL-5tTA: 4 weeks	21042908LJ	12	29
RVΔL-5tTA: 4 weeks	21042908LJ	13	14
RVΔL-5tTA: 4 weeks	21042908LJ	14	27
RVΔL-5tTA: 4 weeks	21042908LJ	15	57
RVΔL-5tTA: 4 weeks	21042908LJ	total:	1329

Condition	Mouse number	Cell counts
RV∆GL-Flpo: 1 week	21021505LJ	22
RV∆GL-Flpo: 1 week	21021506LJ	18
RV∆GL-Flpo: 1 week	21021507LJ	121
RV∆GL-Flpo: 1 week	21021508LJ	2
RV∆GL-Flpo: 1 week	21052505LJ	7
RV∆GL-Flpo: 1 week	21052506LJ	8
RV∆GL-Flpo: 1 week	21052507LJ	98
RV∆GL-Flpo: 1 week	21052508LJ	6
RV∆GL-Flpo: 1 week	Mean:	35.25
RV∆L-Flpo: 1 week	21021805LJ	3093
RV∆L-Flpo: 1 week	21021806LJ	320
RV∆L-Flpo: 1 week	21021807LJ	311
RVΔL-Flpo: 1 week	21021808LJ	263
RV∆L-Flpo: 1 week	21052607LJ	47
RVΔL-Flpo: 1 week	21052608LJ	2161
RVΔL-Flpo: 1 week	21060302LJ	365
RVΔL-Flpo: 1 week	21060303LJ	238
RVΔL-Flpo: 1 week	Mean:	849.75
RVΔGL-Flpo: 4 weeks	21021501LJ	80
RVΔGL-Flpo: 4 weeks	21021502LJ	62
RVΔGL-Flpo: 4 weeks	21021503LJ	3254
RVΔGL-Flpo: 4 weeks	21021503LJ	237
RVΔGL-Flpo: 4 weeks	21052501LJ	43
RVΔGL-Flpo: 4 weeks	21052502LJ	14
RVΔGL-Flpo: 4 weeks	21052502LJ	130
RVΔGL-Flpo: 4 weeks	21052504LJ	65
RVΔGL-Flpo: 4 weeks	Mean:	485.625
RVAL-Flpo: 4 weeks	21021801	4614
RVAL-Flpo: 4 weeks	21021801LJ	3006
RVAL-Flpo: 4 weeks	21021802LJ	1847
· ·	21021803LJ	3331
RVAL-Flpo: 4 weeks		
RVΔL-Flpo: 4 weeks	21052601LJ	1369
RVAL-Flpo: 4 weeks	21052602LJ	2919
RVAL-Flpo: 4 weeks	21052603LJ	3730
RVΔL-Flpo: 4 weeks	21052606LJ	3454
RVΔL-Flpo: 4 weeks	Mean:	3033.75
RVΔGL-Cre: 1 week	21021703LJ	13484
RVΔGL-Cre: 1 week	21021704LJ	14635
RVΔGL-Cre: 1 week	21021707LJ	10647
RVΔGL-Cre: 1 week	21021708LJ	10845
RVΔGL-Cre: 1 week	Mean:	12402.75
RVΔL-Cre: 1 week	21021905LJ	16907
RVΔL-Cre: 1 week	21021906LJ	17923
RVΔL-Cre: 1 week	21021907LJ	18751
RVΔL-Cre: 1 week	21021908LJ	16257
RVΔL-Cre: 1 week	Mean:	17459.5
RVAGL-Cre: 4 weeks	21021701LJ	19156
RVAGL-Cre: 4 weeks	21021702LJ	17935
RVAGL-Cre: 4 weeks	21021705LJ	18539
RV∆GL-Cre: 4 weeks	21021706LJ	17938
RV∆GL-Cre: 4 weeks	Mean:	18392
RVAL-Cre: 4 weeks	21021901LJ	21743
RVAL-Cre: 4 weeks	21021902LJ	24773
RV∆L-Cre: 4 weeks	21021903LJ	23026
RVAL-Cre: 4 weeks	21021904LJ	22272
RVAL-Cre: 4 weeks	Mean:	22953.5
RVΔL-5tTA: 1 week	21042901LJ	339
RVΔL-5tTA: 1 week	21042902LJ	1411
	21042903LJ	796
RVΔL-5tTA: 1 week		2274
RVΔL-5tTA: 1 week RVΔL-5tTA: 1 week	21060301LJ	2271
	21060301LJ Mean:	1204.25
RVΔL-5tTA: 1 week		
RVΔL-5tTA: 1 week RVΔL-5tTA: 1 week	Mean:	1204.25
RVΔL-5tTA: 1 week RVΔL-5tTA: 1 week RVΔL-5tTA: 4 weeks	Mean: 21042905LJ	1204.25 829
RVΔL-5tTA: 1 week RVΔL-5tTA: 1 week RVΔL-5tTA: 4 weeks RVΔL-5tTA: 4 weeks	Mean:           21042905LJ           21042906LJ	1204.25 829 1574

80	4614
62	3006
3254	1847
237	3331
43	1369
14	2919
130	3730
65	3454

Anova: Single Factor

#### SUMMARY

Groups	Count	Sum	Average	Variance
RV∆GL-Flpo 4 weeks	8	3885	485.625	1255920.84
RV∆L-Flpo 4 weeks	8	24270	3033.75	1062946.79

### ANOVA

Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	25971764.06	1	25971764.1	22.4003852	0.00032063	4.60010994
Within Groups	16232073.38	14	1159433.81			
Total	42203837.44	15				

RV∆GL-Flpo 1 week	RV∆GL-Flpo 4 weeks
22	80
18	62
121	3254
2	237
7	43
8	14
98	130
6	65

9618061.938

#### Anova: Single Factor

#### SUMMARY

Total

Groups	Count	Sum	Average	Variance
RV∆GL-Flpo 1 week	8	282	35.25	2180.78571
RV∆GL-Flpo 4 weeks	8	3885	485.625	1255920.84

#### ANOVA Source of Variation SS MS F df P-value 811350.563 1.28980131 0.27515341 4.60010994 **Between Groups** 1 811350.5625 Within Groups 8806711.375 14 629050.813 15

F crit

RVAGL-Flpo 4 weeks	RV∆L-Flpo 1 week
--------------------	------------------

80	3093
62	320
3254	311
237	263

Anova: Single Factor

SUMMARY				
Groups	Count	Sum	Average	Variance
RV∆GL-Flpo 4 weeks	4	3633	908.25	2451752.25
RV∆L-Flpo 1 week	4	3987	996.75	1953632.25

ANOVA						
Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	15664.5	1	15664.5	0.00711152	0.93553752	5.98737761
Within Groups	13216153.5	6	2202692.25			
Total	13231818	7				

RV∆L-Flpo 4 weeks	RV∆GL-Flpo 1 week
4614	22
3006	18
1847	121
3331	2

3730

3454

Anova: Single Factor

365

238

SUMMARY				
Groups	Count	Sum	Average	Variance
RV∆L-Flpo 4 weeks	4	12798	3199.5	1294933.67
RV∆GL-Flpo 1 week	4	163	40.75	2936.91667

ANOVA						
Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	19955403.13	1	19955403.1	30.7509907	0.00145233	5.98737761
Within Groups	3893611.75	6	648935.292			
Total	23849014.88	7				
RV∆L-Flpo 1 week	RV∆L-Flpo 4 weeks					
3093	4614					
320	3006					
311	1847					
263	3331					
47	1369					
2161	2919					

#### Anova: Single Factor

#### SUMMARY

Groups	Count	Sum	Average	Variance
RV∆L-Flpo 1 week	8	6798	849.75	1274333.93
RV∆L-Flpo 4 weeks	8	24270	3033.75	1062946.79

### ANOVA

Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	19079424	1	19079424	16.3261724	0.00121549	4.60010994
Within Groups	16360965	14	1168640.36			
Total	35440389	15				

### RVΔGL-Flpo 1 week RVΔL-Flpo 1 week

22	3093
18	320
121	311
2	263
7	47
8 98	2161
98	365
6	238

#### Anova: Single Factor

SUMMARY				
Groups	Count	Sum	Average	Variance
RV∆GL-Flpo 1 week	8	282	35.25	2180.78571
RV∆L-Flpo 1 week	8	6798	849.75	1274333.93

#### ANOVA Source of Variation P-value SS df MS F F crit 0.06079134 4.60010994 **Between Groups** 2653641 1 2653641 4.1576348 Within Groups 8935603 14 638257.357 Total 11589244 15

RV∆GL-Cre 4 weeks	RV∆L-Cre 4 weeks
19156	21743
17935	24773
18539	23026
17938	22272

#### Anova: Single Factor

#### SUMMARY

Groups	Count	Sum	Average	Variance
RV∆GL-Cre 4 weeks	4	73568	18392	340090
RV∆L-Cre 4 weeks	4	91814	22953.5	1748529.67

ANOVA			
Source of Variation	SS	df	MS F P-value F crit
Between Groups	41614564.5	1	41614564.5 39.8488678 0.00073769 5.9873776
Within Groups	6265859	6	1044309.83
Total	47880423.5	7	

RV∆GL-Cre 4 weeks	RV∆GL-Cre 1 week
19156	13484
17935	14635
18539	10647
17938	10845

#### Anova: Single Factor

#### SUMMARY

Groups	Count	Sum	Average	Variance
RV∆GL-Cre 4 weeks	4	73568	18392	340090
RV∆GL-Cre 1 week	4	49611	12402.75	3887094.92

#### ANOVA

Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	71742231.13	1	71742231.1	33.943266	0.00112486	5.98737761
Within Groups	12681554.75	6	2113592.46			
Total	84423785.88	7				

RV∆GL-Cre 4 weeks	RV∆L-Cre 1 week
19156	16907
17935	17923
18539	18751
17938	16257

#### Anova: Single Factor

#### SUMMARY

Groups	Count	Sum	Average	Variance
RV∆GL-Cre 4 weeks	4	73568	18392	340090
RV∆L-Cre 1 week	4	69838	17459.5	1211355.67

ANOVA						
Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	1739112.5	1	1739112.5	2.24192511	0.1849584	5.98737761
Within Groups	4654337	6	775722.833			
Total	6393449.5	7				

RV∆L-Cre 4 weeks	RV∆GL-Cre 1 week
21743	13484
24773	14635
23026	10647
22272	10845

Anova: Single Factor

SUMMARY						
Groups	Count	Sum	Average	Variance		
RV∆L-Cre 4 weeks	4	91814	22953.5	1748529.67		
RV∆GL-Cre 1 week	4	49611	12402.75	3887094.92		

ANOVA							
Source of Variation	SS	df	MS	F	P-value	F crit	
Between Groups	222636651.1	1	222636651	79.010462	0.00011291	5.98737761	
Within Groups	16906873.75	6	2817812.29				
Total	239543524.9	7					

RV∆L-Cre 4 weeks	RV∆L-Cre 1 week
21743	16907
24773	17923
23026	18751
22272	16257

Anova: Single Factor

SUMMARY						
Groups	Count	Sum	Average	Variance		
RV∆L-Cre 4 weeks	4	91814	22953.5	1748529.67		
RV∆L-Cre 1 week	4	69838	17459.5	1211355.67		

ANOVA						
Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	60368072	1	60368072	40.790818	0.00069327	5.98737761
Within Groups	8879656	6	1479942.67			
Total	69247728	7				
RV∆GL-Cre 1 week	RV∆L-Cre 1 week					

RVDGL-Cre I week	RVAL-Cre I week
13484	16907
14635	17923
10647	18751
10845	16257

Anova: Single Factor

Groups	Count	Sum	Average	Variance
RV∆GL-Cre 1 week	4	49611	12402.75	3887094.92
RV∆L-Cre 1 week	4	69838	17459.5	1211355.67

Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	51141441.13	 1	51141441.1		0.00419681	
Within Groups	15295351.75	6	2549225.29	20.001302	0.00419001	5.56757761
Total	66436792.88	7				
RVΔL-5tTA 1 week	RVΔL-5tTA 4 weeks					
339	829	7				
1411	1574					
796	499					
2271	1329					
SUMMARY						
Groups	Count	Sum	Average	Variance	-	
RV∆L-5tTA 1 week	4	4817	1204.25	698675.583	-	
RV∆L-5tTA 4 weeks	4	4231	1057.75	234872.917	-	
ANOVA						
Source of Variation	SS	df	MS	F	P-value	F crit
Between Groups	42924.5	1	42924.5	0.09195987	0.77193993	5.98737761
Within Groups	2800645.5	6	466774.25			

Comparison	p-value
RVAGL-Flpo 4 weeks vs RVAL-Flpo 4 weeks	0.000320625
RVΔGL-Flpo 4 weeks vs RVΔGL-Flpo 1 week	0.27515341
$RV\Delta GL$ -Flpo 4 weeks vs $RV\Delta L$ -Flpo 1 week	0.93553752
RVAL-Flpo 4 weeks vs RVAGL-Flpo 1 week	0.001452333
RVAL-Flpo 4 weeks vs RVAL-Flpo 1 week	0.001215493
RVΔGL-Flpo 1 week vs RVΔL-Flpo 1 week	0.060791343
RVAGL-Cre 4 weeks vs RVAL-Cre 4 weeks	0.000737695
RVAGL-Cre 4 weeks vs RVAGL-Cre 1 week	0.001124862
RVAGL-Cre 4 weeks vs RVAL-Cre 1 weeks	0.184958403
RVAL-Cre 4 weeks vs RVAGL-Cre 1 week	0.000112909
RVAL-Cre 4 weeks vs RVAL-Cre 1 week	0.000693266
RVΔGL-Cre 1 week vs RVΔL-Cre 1 week	0.004196815
RVAL-5tTA 1 week vs RVAL-5tTA 4 weeks	0.77193993

- 812 Video S1. RV $\Delta$ L-Cre-labeled cortical neurons at 2 weeks vs 10 weeks postinjection, Related to
- 813 Figure 3
- 3-dimensional rendering of the same cortical volume shown in Figure 3, panel B.
- 815816 See external
- 816 See external file.817
- 818

# File S3. Cell counts and statistics for structural two-photon imaging experiments, Related to Figure 3

- 822 See following pages.
- 823
- 824

RV∆GL-Cre: cell counts	Animal-1 FOV-1	Animal-1 FOV-2	Animal-2 FOV-1	Animal-2 FOV-2	Animal-3 FOV-1	Animal-3 FOV-2	Animal-4 FOV-1	Animal-4 FOV-2
Week-1	300	315	219	318	435	288	203	220
Week-2	519	359	269	546	488	364	321	354
Week-3	537	390	305	569	505	443	369	427
Week-4	538	403	317	572	518	445	372	426
Week-6	537	403	319	571	515	451	370	424
Week-12	535	400	319	567	514	443	369	424
Week-14			319	567	513	442	368	421
Week-16			319					
RV∆GL-Cre: percentage to week-1	Animal-1 FOV-1	Animal-1 FOV-2	Animal-2 FOV-1	Animal-2 FOV-2	Animal-3 FOV-1	Animal-3 FOV-2	Animal-4 FOV-1	Animal-4 FOV-2
Week-1	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Week-2	1.73	1.14	1.23	1.72	1.12	1.26	1.58	1.61
Week-3	1.79	1.24	1.39	1.79	1.16	1.54	1.82	1.94
Week-4	1.79	1.28	1.45	1.80	1.19	1.55	1.83	1.94
Week-6	1.79	1.28	1.46	1.80	1.18	1.57	1.82	1.93
Week-12	1.78	1.27	1.46	1.78	1.18	1.54	1.82	1.93
Week-14			1.46	1.78	1.18	1.53	1.81	1.91
Week-16			1.46					
GL-Cre: comparison between week-1 and week-4			Animal-2 FOV-1	Animal-2 FOV-2	Animal-3 FOV-1	Animal-3 FOV-2	Animal-4 FOV-1	Animal-4 FOV-

Week-1	300	315	219	318	435	288	203	220
Week-4	538	403	317	572	518	445	372	426
Increase (Week-4 - Week-1)	238	88	98	254	83	157	169	206
% increase (Week-4 - Week-1)	79.33%	27.94%	44.75%	79.87%	19.08%	54.51%	83.25%	93.64%
Increase (Week-12 - Week-4)	-3	-3	2	-5	-4	-2	-3	-2
% increase (Week-12 - Week-4)	-0.56%	-0.74%	0.63%	-0.87%	-0.77%	-0.45%	-0.81%	-0.47%

t-Test: Paired Two Sam	ple for Means	
	Week-1	Week-4
Mean	287.25	448.875
Variance	5712.5	7689.267857
Observations	8	8
Pearson Correlation	0.665	513457
Hypothesized Mean Difference		0
df		7
t Stat	-6.754	173154
P(T<=t) one-tail	0.000	131934
t Critical one-tail	1.894	578605
P(T<=t) two-tail	0.000	263868
t Critical two-tail	2.364	624252

t-Test: Paired Two Sample	t-Test: Paired Two Sample for Means						
	Week-4	Week-12					
Mean	448.875	446.375					
Variance	7689.267857	7407.410714					
Observations	8	8					
Pearson Correlation	0.999	890399					
Hypothesized Mean Difference		0					
df		7					
t Stat	3.415	650255					
P(T<=t) one-tail	0.005	600716					
t Critical one-tail	1.894	578605					
P(T<=t) two-tail	0.011	201433					
t Critical two-tail	2.364	624252					

% increase from 1 week to 4 weeks:								
RV∆GL-Cre	79.33%	27.94%	44.75%	79.87%	19.08%	54.51%	83.25%	93.64%
RV∆L-Cre	84.38%	84.41%	49.57%	70.25%	54.88%	67.66%	40.66%	93.26%

Unpaired t test	
Table Analyzed	% increase
P value	0.5187
P value summary	ns
Significantly different (P < 0.05)?	No
One- or two-tailed P value?	Two-tailed
t, df	t=0.6621, df=14
How big is the difference?	•
Mean of RV∆GL-Cre	0.603
Mean of RV∆L-Cre	0.6813
Difference between means (B - A) ± SEM	0.07836 ± 0.1184
95% confidence interval	-0.1755 to 0.3322
R squared (eta squared)	0.03036
F test to compare variances	
F, DFn, Dfd	2.216, 7, 7
P value	0.3158
P value summary	ns
Significantly different (P < 0.05)?	No
Data analyzed	1
Sample size, RV∆GL-Cre	8
Sample size, RV∆L-Cre	8

% increase from 4 weeks to 12 weeks:									
RV∆GL-Cre	-0.56%	-0.74%	0.63%	-0.87%	-0.77%	-0.45%	-0.81%	-0.47%	
RV∆L-Cre	0.48%	-0.29%	2.31%	-1.46%	3.30%	0.00%	0.78%	0.58%	

Unpaired t test	
P value	0.0451
P value summary	*
Significantly different (P < 0.05)?	Yes
One- or two-tailed P value?	Two-tailed
t, df	t=2.199, df=14
How big is the difference?	
Mean of RV∆GL-Cre	-0.005054
Mean of RV∆L-Cre	0.007135
Difference between means (B - A) ± SEM	.01219 ± 0.005542
95% confidence interval	0003030 to 0.0240
R squared (eta squared)	0.2568
F test to compare variances	
F, DFn, Dfd	9.402, 7, 7
P value	0.0085
P value summary	**
Significantly different (P < 0.05)?	Yes
Data analyzed	
Sample size, RV∆GL-Cre	8
Sample size, RV∆L-Cre	8


RV∆L-Cre: cell counts	Animal-1 FOV-1	Animal-1 FOV-2	Animal-2 FOV-1	Animal-2 FOV-2	Animal-3 FOV-1	Animal-3 FOV-2	Animal-4 FOV-1	Animal-4 FOV-2
Week-1	224	186	232	242	215	167	182	178
Week-2	331	307	300	298	270	237	200	228
Week-3	396	340	341	378	289	279	253	304
Week-4	413	343	347	412	333	280	256	344
Week-6	409	342	347	413	342	283	255	345
Week-12	415	342	355	406	344	280	258	346
Week 14	415	342	354	406	344	280		
Week-16				406	344	280		

RV∆L-Cre: percentage to week-1	Animal-1 FOV-1	Animal-1 FOV-2	Animal-2 FOV-1	Animal-2 FOV-2	Animal-3 FOV-1	Animal-3 FOV-2	Animal-4 FOV-1	Animal-4 FOV-2
Week-1	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Week-2	1.48	1.65	1.29	1.23	1.26	1.42	1.10	1.28
Week-3	1.77	1.83	1.47	1.56	1.34	1.67	1.39	1.71
Week-4	1.84	1.84	1.50	1.70	1.55	1.68	1.41	1.93
Week-6	1.83	1.84	1.50	1.71	1.59	1.69	1.40	1.94
Week-12	1.85	1.84	1.53	1.68	1.60	1.68	1.42	1.94
Week 14	1.85	1.84	1.53	1.68	1.60	1.68		
Week-16				1.68	1.60	1.68		

RVAL-Cre: comparison between week-1 and week-4	Animal-1 FOV-1	Animal-1 FOV-2	Animal-2 FOV-1	Animal-2 FOV-2	Animal-3 FOV-1	Animal-3 FOV-2	Animal-4 FOV-1	Animal-4 FOV-2
Week-1	224	186	232	242	215	167	182	178
Week-4	413	343	347	412	333	280	256	344
Increase (Week-4 - Week-1)	189	157	115	170	118	113	74	166
% increase (Week-4 - Week-1)	84.38%	84.41%	49.57%	70.25%	54.88%	67.66%	40.66%	93.26%
Increase (Week-12 - Week-4)	2	-1	8	-6	11	0	2	2
% increase (Week-12 - Week-4)	0.48%	-0.29%	2.31%	-1.46%	3.30%	0.00%	0.78%	0.58%

t-Test: Paired Two Sample for Means						
	Week-1	Week-4				
Mean	203.25	341				
Variance	799.6428571	3040.571429				
Observations	8	8				
Pearson Correlation	0.7540	0.754099973				
Hypothesized Mean Difference		)				
df		7				
t Stat	-10.09	-10.09862351				
P(T<=t) one-tail	1.002	1.00266E-05				
t Critical one-tail	1.8945	1.894578605				
P(T<=t) two-tail	2.005	2.00531E-05				
t Critical two-tail	2.3646	2.364624252				

t-Test: Paired Two Sample for Means						
	Week-4	Week-12				
Mean	341	343.25				
Variance	3040.571429	2928.785714				
Observations	8	8				
Pearson Correlation	0.9955	0.995543784				
Hypothesized Mean Difference		0				
df		7				
t Stat	-1.210	-1.210419877				
P(T<=t) one-tail	0.132	0.13269902				
t Critical one-tail	1.8945	1.894578605				
P(T<=t) two-tail	0.2653	0.265398039				
t Critical two-tail	2.3646	2.364624252				




825 826

#### Figure S4. GCaMP6s signals and tuning curves of 8 example V1 neurons at 16 weeks postinjection, **Related to Figure 4** 827

These data were obtained with drifting gratings presented at 12 directions of motion and 5 temporal 828 frequencies, repeated 10 times (tuning curve: mean  $\Delta F/F \pm s.e.m$ ; GCaMP6s signals: mean  $\Delta F/F$ ) at two 829 different FOVs at the 16-week timepoint. 830

831

832



B33 Orientation (deg)
 B34 Figure S5. More examples showing long-term stability of orientation and temporal frequency tuning
 B35 in RV∆L-Cre labeled neurons, Related to Figure 4

- (A) Maximum intensity projections of the same FOV at 4 weeks, 10 weeks, and 14 weeks postinjection.
- 837 Scale bar: 100 µm, applies to all images.
- 838 (B) Visual responses of the three circled cells in panel **a** measured at the three different timepoints. Data
- 839 were obtained with drifting gratings presented at 12 directions of motion and 5 temporal frequencies (mean  $\Delta F/F \pm s.e.m.$ , averaged over 10 repeats).
- 841 842

### Video S2. GCaMP6s signals of visual cortical neurons 16 weeks after injection of RV∆L-Cre, Related to Figure 4

Video shows responses to 10 repeats of drifting gratings at 12 directions of motion at one temporal frequency (1 Hz) over a total of 480 seconds.

- 847
- 848 See external file.
- 849
- 850

## File S4. Tuned cell counts and statistics for functional two-photon imaging experiments, Related to Figure 4

- 853
- 854 See following page.